

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/000418

International filing date: 07 January 2005 (07.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/557,232
Filing date: 29 March 2004 (29.03.2004)

Date of receipt at the International Bureau: 21 February 2005 (21.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1283246

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 09, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/557,232

FILING DATE: *March 29, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/00418*




Certified by

W. F. Dudas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

1834 U.S. PTO
032904

Please type a plus sign (+) inside this box → 

PTO/SB/16 (2-01)
Approved for use through 10/31/2002. OMB 0851-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Docket Number: 228272

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Moghis U.	Ahmad	Wadsworth, Illinois
Saifuddin	Sheikh	Waukegan, Illinois
Shoukath M.	Ali	Beach Park, Illinois
Pei-Yu	Chien	Highland Park, Illinois
Haris	Jamil	Libertyville, Illinois
Jia-Ai	Zhang	Vernon Hills, Illinois
Sydney	Ugwu	Gurnee, Illinois
Zhi-Yi	Zhang	Gurnee, Illinois
Jinkang	Wang	San Francisco, California
Shastri	Bhamidipati	Buffalo Grove, Illinois
Zafeer	Ahmad	Wadsworth, Illinois
Imran	Ahmad	Wadsworth, Illinois

☒ Additional inventors are being named on the separately numbered sheets attached hereto.

TITLE OF THE INVENTION (280 characters max)
LIPID COMPOSITIONS AND USE THEREOF

CORRESPONDENCE ADDRESS

Direct all correspondence to:
☒ Customer Number 23460
 23460
☐ Leydig, Voit & Mayer, Ltd.
 Two Prudential Plaza, Suite 4900
 180 North Stetson Avenue
 Chicago, Illinois 60601-6780 U.S.A.

ENCLOSED APPLICATION PARTS (check all that apply)

☐ Specification Number of Pages: 66
 (including any claims and abstract)
☒ Drawings (Figs 1 and 4A-4C) Number of Sheets: 4
☒ Application Data Sheet. See 37 CFR 1.76
☐ Power of Attorney
☐ Assignment
☐ CD(s), Number
☒ Other (specify) Appendix - Copy of PCT/US03/33099 (73 pages)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ Applicant claims small entity status. See 37 CFR 1.27.
☐ A check or money order is enclosed to cover the filing fee(s).
☒ The Commissioner is hereby authorized to charge filing fee(s) or credit any overpayment to Deposit Account Number 12-1216. A duplicate copy of this communication is enclosed for that purpose.
☒ The Commissioner is hereby authorized to charge any deficiencies in filing fees to Deposit Account Number 12-1216. A duplicate copy of this communication is enclosed for that purpose.

FILING FEE AMOUNT:
\$80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government:
☒ No.
☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

M. Daniel HEFNER, Registration No. 41,826
 LEYDIG, VOIT & MAYER, LTD.
 Two Prudential Plaza, Suite 4900
 180 North Stetson Avenue
 Chicago, Illinois 60601-6780
 (312) 616-5600 (telephone)
 (312) 616-5700 (facsimile)


Date: March 29, 2004

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as attached or enclosed therein are being deposited with the United States Postal Service on March 29, 2004, in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR 1.10, Mailing Label Number EV 335719175 US, addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christina Masters

Typed or Printed Name of Person Making Deposit
 Provisional Transmittal (Revised 10/1/03)


 Signature of Person Making Deposit

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

LIPID COMPOSITIONS AND USE THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is related to PCT/US03/33099, filed on October 16, 2003, a copy of which is attached as pages A1-A73, and the contents of which in their entirety are incorporated herein by reference thereto.

[0002] This application also is related to United States Provisional Patent Application 60/535,042, filed on January 7, 2004, the contents of which in their entirety are incorporated herein by reference thereto.

[0003] This application also is related to a United States Provisional Patent Application (Serial No. unknown), filed on March 27, 2004 under Express Mail No. EV 335719802 US, the contents of which in their entirety are incorporated herein by reference thereto.

FIELD OF THE INVENTION

[0004] This invention pertains to lipid compositions and their use, particularly as transfection agents

BACKGROUND OF THE INVENTION

[0005] Polynucleotides (such as oligonucleotides, cDNA, plasmids, RNAi, etc.) have potential use as therapeutic agents. For example, antisense oligonucleotides targeted to oncogenes have shown promise in neoplastic diseases, such as cancer. An exemplary agent, an antisense Oligonucleotide (AON) targeted to the mRNA of human c-raf oncogene, is called c-rafAON. c-rafAON is an antineoplastic agent used for the treatment of radiation resistant tumors and multiple myelomas. c-rafAON acts by hybridizing with mRNA to inhibit translation, protein synthesis and tumor growth. Other examples of polynucleotides with therapeutic benefit include RNAi that can also inhibit the expression of genes of interest, such as oncogenes. Plasmids or other vectors containing gene of interest also have therapeutic potential by being able to deliver transgenes of interest to patients.

[0006] While promising in their therapeutic potential, due to their negative charge, agents cannot efficiently penetrate cell membrane to transfect cells. Thus, a delivery system is needed to improve cell transfection and increase therapeutic efficacy of polynucleotides. The use of cationic liposomes to enhance the delivery of oligonucleotides has been reported (US Pat No. 6,559,129 B1 and 6,333,314 B1, Zelphati *et.al.* J. Liposome

Res., 7(1):31-49 (1997)). However, several drawbacks exist with respect to current cationic lipid transfection agents that limit their usefulness as transfection agents.

[0007] For example, many cationic lipids have poor chemical stability. Moreover, liposomes including many cationic lipids exhibit poor loading of the polynucleotides, largely due to the inflexibility of cationic bilayer membranes. Accordingly, many currently available transfection agents are not suitable for transfection with different types of polynucleotides (DNA and RNAi). Furthermore, most available transfection agents, such as LIPOFECTIN®, are not effective in transfecting primary cell cultures. Also, many cationic transfection agents, such as, for example, LIPOFECTIN®, exhibit relatively higher toxicity rendering them unsuitable for *in vivo* use. In light of the foregoing, there remains a need for an effective transfection agent.

[0008] A problem facing medical science is the validation of targets for genetic inhibition or therapeutic intervention. A typical method for validating a target gene as a cause or associated with a particular disorder is to ablate the gene of interest from a line of animals to generate an animal model. A common approach to accomplishing this is to generate a knock-out animal, typically a rodent. However, this approach is burdensome, costly, and time-consuming, when it works. Of course, as many genes that may be important to a particular disease also are crucial for normal development of an animal, it often is not possible to generate a knock-out. Moreover, as many genes contribute to normal physiology as well as the development of diseases, a "compensation effect" can prevent a knock-out animal from functioning as a suitable model or system for validating the target gene. Accordingly, there remains a need for an effective method of validating target genes as contributing to diseases or phenotypes.

BRIEF SUMMARY OF THE INVENTION

[0009] The invention provides a composition, suitable for use as a transfection agent, comprising a cationic cardiolipin analogue and, desirably, another lipid species. The composition of the present invention can facilitate transfection of a wide variety of polynucleotide species (e.g., oligodeoxyribonucleotides, plasmids, RNAi species, etc.). Moreover, the transfection agent of the present invention is effective in promoting transfection of primary cell cultures as well as transformed cells. Also, the inventive transfection agent is suitable for use both *in vitro* and *in vivo*. The inventive composition has additional uses as well, such as delivery of a variety of active agents, dermatological and cosmetic uses, and uses in agriculture.

[0010] A preferred cationic cardiolipin is 1,3-Bis-(1,2-bis-tetradecyloxy-propyl-3-dimethylethoxyammoniumbromide)-propane-2-ol (PCL-2). The composition further preferably comprises a lipid selected from the group of lipids consisting of cholesterol, dioleoylphosphatidylethanolamine (DOPE), 1,2 Dioleoyl-sn-glycero-3-phosphocholine (DOPC), alpha tocopheryl acid succinate and any other phosphatidylcholine. The composition can include an active agent, such as a polynucleotide. The present invention also involves pharmaceutical formulations of c-raf Antisense Oligonucleotide (c-rafAON) and methods for making stable lamellar complexes of an antineoplastic agent to minimize rapid hydrolysis of raf-AON in plasma, reduce *in vivo* clearance, improve cell transfection and increase therapeutic efficacy of c-rafAON.

[0011] The invention further provides a method of introducing an active agent into a cell by contacting the cell with the inventive composition. The invention further provides a method of inhibiting the growth of neoplastic cells and a method of treating a patient suffering from a neoplastic disease by employing the inventive composition, wherein an active agent is an antineoplastic agent. The invention further provides a method for validating a genetic target, comprising (a) administering to a cell a composition comprising a cationic liposome and an RNAi, whereby the RNAi enters the cell inhibits the expression of a gene within the cell and (b) assaying for the inhibition of the gene.

[0012] The invention also provides a fluorescent cationic cardiolipin analogue and compositions including such analogues. Using a cationic cardiolipin analogue, the invention provides a method of tracking the migration of a lipid substance within an animal. This invention further provides a luminescent cationic cardiolipin analogue and composition including such analogues that will be helpful in measurements requiring higher decay time than fluorescent analogues.

[0013] These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

DETAILED DESCRIPTION OF THE INVENTION

[0014] In one embodiment, the invention provides a composition, comprising a cationic cardiolipin analogue and, desirably, another lipid species. Suitable cationic cardiolipin analogues for use in the inventive composition are described in international patent application PCT/US03/33099, which is incorporated herein by reference and a copy of which is included with this application. A most preferred cationic cardiolipin analogue for inclusion in the inventive composition is 1,3-Bis-(1,2-bis-tetradecyloxy-propyl-3-

dimethylethoxyammoniumbromide)-propane-2-ol (PCL-2), which is identified in PCT/US03/33099 as compound 19.

[0015] The invention also provides fluorescent and/or luminescent cationic cardiolipin analogues. For example, the fluorescent analogue can comprise a cationic cardiolipin molecule (such as described in international patent application PCT/US03/33099) as compound 19 conjugated to a fluorescent moiety. Examples of fluorescent moieties includes fluorescein derivatives such as [N-(5-fluoresceinyl)-5-carbamylpentanoic acid] and the like, 2,1,3-benzooxadiazole derivatives, coumarin derivatives such as 3-bromoacetyl-6,7-methylenedioxy coumarin, 4-(7-diethylaminocoumarin-3-yl) benzeneisocyanate and the like, 4-(4,5-diphenyl-1H-imidazo-2-yl) benzoyl chloride, 2-dansylethyl chloroformate, 5-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride and the like. A preferred fluorescent analogue is a fluorescent analogue of PCL-2. The fluorescent cationic cardiolipin analogue can be constructed by any suitable method for conjugating fluorescent moieties to molecules such as cationic lipids, many of which are known to those of ordinary skill in the art. Luminescent analogues can be also synthesized by ordinary skill in the art. The fluorescent or luminescent analogues can be employed in the invention.

[0016] Fluorescent and luminescent cationic cardiolipin of the present invention can be used to track the path/ location of cationic cardiolipin liposomes. Fluorescent and luminescent cationic cardiolipin of the present invention also can be used to investigate the distribution of liposome uptake and gene delivery in various tissues. Also, fluorescent and luminescent cationic cardiolipin of the present invention can be used to investigate the mechanism of delivery of genes inside the cell.

[0017] As noted herein, any suitable amount of cationic cardiolipin can be used in the composition, desirably, the cationic cardiolipin PCL-2 is present at between about 0.3 mM and about 20 mM, such as between about 1 mM and about 15 mM, but the composition can include more or less cationic cardiolipin PCL-2 as desired. In certain preferred compositions, the cationic cardiolipin PCL-2 is present at about 0.35 mM.

[0018] Desirably, the composition further comprises at least one lipid in addition to the cationic cardiolipin analogue. The additional lipid(s) can be any desired lipid species suitable for forming the composition of interest, such as those described in PCT/US03/33099. Preferred lipids for inclusion in the inventive composition are selected from the group of lipids consisting of cholesterol, cholesterol derivatives, dioleoylphosphatidylethanolamine (DOPE), 1,2 Dioleoyl-sn-glycero-3-phosphocholine

(DOPC), alpha tocopheryl acid succinate and any other phosphatidylcholine. Typically, the total lipid concentration of the composition is between about 1.0 mg/mL and about 60 mg/mL (such as at least about 5.0 mg/mL or at least about 10 mg/mL or even at least about 10 mg/mL and up to about 50 mg/mL, or up to about 40 mg/mL or even up to about 30 mg/mL) but can be higher or lower than these amounts as desired.

[0019] A most preferred composition in accordance with the present invention includes DOPC, cationic cardiolipin PCL-2, and cholesterol. In this composition, the cationic cardiolipin, DOPC, and cholesterol can be present in any suitable proportion. However, such a composition preferably has a percent molar ratio of DOPC:PCL-2:cholesterol of between about (50-65):(25-35):(5-20). Also, desirably such a composition further includes D-alpha tocopheryl acid succinate. The D-alpha tocopheryl acid succinate can be present in any suitable amount in the composition, but desirably is present at between about 0.1 wt % and about 1 wt %, most preferably at about 0.2 wt%. However, the amount of D-alpha tocopheryl acid succinate can be more or less than these amounts, as desired.

[0020] Another preferred composition according to the invention includes cationic cardiolipin PCL-2 and cholesterol. Within such a composition, the cationic cardiolipin and cholesterol can be present in any suitable molar ratio. However, desirably the molar ratio of PCL-2 and cholesterol is between 1:3 and 6:1, such as between 1:3 and 3:1, or between 2:3 and 3:2, or even between 1:2 and 2:1.

[0021] Another preferred composition according to the invention includes PCL-2 and DOPE. Within such a composition, the cationic cardiolipin and DOPE can be present in any suitable molar ratio. However, desirably the molar ratio of PCL-2 and DOPE is between 1:3 and 6:1, such as between 1:3 and 3:1, or between 2:3 and 3:2, or even between 1:2 and 2:1.

[0022] In addition to the cationic cardiolipin and other lipids, the composition can include stabilizers, absorption enhancers, antioxidants, phospholipids, biodegradable polymers and medicinally active agents among other ingredients. Suitable antioxidants include compounds such as ascorbic acid, tocopherol, and deteroxime mesylate. Suitable absorption enhancers include Na-salicylate-chenodeoxy cholate, Na deoxycholate, polyoxyethylene 9-lauryl ether, chenodeoxy cholate-deoxycholate and polyoxyethylene 9-lauryl ether, monolein, Na tauro-24,25-dihydrofusidate, Na taurodeoxycholate, Na glycochenodeoxycholate, oleic acid, linoleic acid, and linolenic acid. Polymeric absorption enhancers can also be included such as polyoxyethylene ethers, polyoxyethylene sorbitan

esters, polyoxyethylene 10-lauryl ether, polyoxyethylene 16-lauryl ether, and azone (1-dodecylazacycloheptane-2-one).

[0023] In some embodiments, it is preferable for the inventive composition, especially liposomal composition to include a targeting agent, such as carbohydrate or a protein or other ligand that binds to a specific substrate, such as antibodies (or fragments thereof) or ligand that recognize cellular receptors. The inclusion of such agents (such as a carbohydrate or one or more proteins selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands such as an antibody to a cellular receptor and mixtures thereof) can facilitate targeting the composition to a predetermined tissue or cell type.

[0024] In a preferred embodiment, the composition includes at least one sugar or biodegradable polymer. Examples of suitable sugars and polymers include sucrose, lactose, trehalose, dextrose, epichlorohydrin, branched hydrophilic polymers of sucrose, polyethylene glycols, polyvinyl alcohols, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide, polyoxyethylene, polyoxypropylene, polyvinylpyrrolidone, polypropyrolidone, dextran, cellulose acetate, sodium alginate, N, N-diethylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters. A preferred sugar for inclusion in the inventive composition is sucrose. Where the sugar or polymer is present, it typically represents between about 1 wt% and about 20 wt% of the composition, such as between about 5 wt% and about 30 wt%. Especially where the sugar is sucrose, a suitable amount of sugar for inclusion in the composition is 10-12 wt%. Additionally, the composition also can include carriers, such as physiologically acceptable carriers. Suitable carriers for physiological (e.g., medical, veterinary, experimental, etc.) uses are physiologically-compatible buffers (e.g., phosphate-buffered saline (PBS), HEPES, etc.), many of which are known to those of ordinary skill in the art.

[0025] For physiological use, the pH of the composition should approximate the pH of the cells or animal to which the composition is to be delivered. For such uses, the composition typically has a pH of between about 7 and about 8, such as between about 7.2 and about 7.8 or between about 7.4 and about 7.5 (e.g., about 7.5). However, the pH of the composition can vary considerably depending on its desired use. It is within the ordinary skill of the art to select a suitable pH for a desired use. Thus, in some embodiments, the pH of the composition can be adjusted to be acidic (e.g., between about 2 and about 6.9, such as

between about 3 and about 6 or between about 4 and about 5). In other applications, it is desirable for the pH of the composition to be alkaline (e.g., between about 7.1 and about 11, or between about 8 and about 10, such as about 9). The pH of the composition can be adjusted using suitable acidic or alkaline buffers as are known to those of ordinary skill in the art.

[0026] The composition can be of any suitable form, such as liposomal formulations, complexes, emulsions, suspensions, etc. Such formulations can be prepared by any suitable technique, depending on the type of composition, which are known to those of ordinary skill in the art. A preferred composition is a liposomal composition or other composition containing lipid vesicles. Such composition can include unilamellar or multilamellar vesicles, or mixtures thereof. Any suitable technique can be employed to produce such a liposomal formulation. Suitable techniques include the thin-film hydration method, reverse phase evaporation, ethanol injection, etc. For example, lipophilic liposome-forming ingredients can be dissolved or dispersed in a suitable solvent or combination of solvents and dried. Suitable solvents include any non-polar or slightly polar solvent, such as *t*-butanol, ethanol, methanol, chloroform, or acetone that can be evaporated without leaving a pharmaceutically unacceptable residue. Drying can be by any suitable means such as lyophilization, use of a rotary dryer, etc. Hydrophilic ingredients, such as some pharmaceutical agents, preservatives, and other agents, can be dissolved in polar solvents, including water, which can be mixed with the lipid phase either prior to drying or upon reconstitution. Mixing the dried lipophilic ingredients with the hydrophilic mixture can form liposomes. Mixing the polar solution with the dry lipid film can be by any means that strongly homogenizes the mixture. Vortexing, magnetic stirring and/or sonicating can effect the homogenization.

[0027] Where active agents are included in the liposomes they can be dissolved or dispersed in a suitable solvent and added to the liposome mixture prior to mixing. Typically hydrophilic active agents will be added directly to the polar solvent and hydrophobic active agents will be added to the nonpolar solvent used to dissolve the other ingredients but this is not required. The active agent could be dissolved in a third solvent or solvent mixture and added to the mixture of polar solvent with the lipid film prior to homogenizing the mixture.

[0028] The liposomes of the present invention can be multi or unilamellar vesicles depending on the particular composition and procedure to make them. Liposomes can be prepared to have substantially homogeneous sizes in a selected size range, such as about 1 micron or less, or about 500 nm or less, about 200 nm or less, or about 100 nm or less.

Particle size has been shown to play a major role in liposome biodistribution and the route of cell entry. Larger liposomes are distributed primarily to the reticuloendothelial (RES) system with negligible amounts in other tissues, whereas smaller liposomes are localized to other organs. Additionally, the clearance of multilamellar vesicles of heterogeneous size distribution follows a biphasic pattern, with rapid clearance of larger liposomes and a slow rate of clearance of small liposomes. Limited information is available on the biodistribution of cationic liposomes containing oligonucleotides. Letsinger and colleagues previously reported that oligonucleotides complexed with cationic liposomes, approximately 2.0 microns in diameter, are transiently taken up by the lungs followed by rapid distribution to liver. Recent studies demonstrated that endocytosis is the principal pathway for delivery of oligonucleotides via cationic liposomes. Preferably, the liposomal lamellar complex formulation of the present invention includes small liposomes so as to slow the rate of clearance of the active agent. One effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through that membrane. For physiological use, it is preferable for the liposomes to be extruded through 0.22 μm filters or less to effect sterilization of the formulation. Desirably, the mean size of the liposomes is between about 50 nm and about 250 nm, such as between about 100 nm and about 200 nm or between about 150 nm and 250 nm. Preferably, the size distribution of the liposomes is substantially uniform. Moreover, within a preparation, desirably, about 99% of the liposomes have a diameter less than about 500 nm (i.e., D99 less than about 500 nm), and desirably, the D99 of a liposomal composition according to the invention is between about 170 nm and about 500 nm, such as between about 200 nm and about 350 nm or between about 250 nm and about 300 nm).

[0029] A preferred manufacturing protocol is represented as a flowchart in Figure 1. This process involves dissolving: i) the lipid excipients, namely, DOPC, cholesterol, PCL-2 and D-Alpha tocopheryl acid succinate in dehydrated ethanol and ii) the active ingredient – a polynucleotide (indicated as a c-raf-1 antisense oligonucleotide in Figure 1), and sucrose in sterile water for injection. Ethanolic lipid solution is added to aqueous active solution to form liposomes. Following *quantum sufficit* (QS) to batch weight according to which the product weight is brought up to the desired weight depending on the batch size, liposomes are size reduced by extrusion three times through 0.2 μ pore size polycarbonate membrane filters and five times through 0.1 μ pore size polycarbonate membrane filters to meet size specification. . Ethanol added is removed from extruded liposomes by rotary evaporation under vacuum. After adjusting the product weight to the weight prior to solvent removal

with sterile water for injection, the product is filtered through 0.22 μ sterilizing filter, filled in sterile vials, stoppered and sealed. This process is used to manufacture the formulation at 10-20 kilogram scale.

[0030] It has been found that the composition of the present invention is stable. In this sense, the composition can be stored under refrigeration and at room temperature for an extended period of time. Generally, the composition is stable under such conditions for at least about 2 months. Stability can be assessed by measuring a change in the constitution of the composition over a desired time frame. For example, the composition can be considered stable if, after two months storage at either room temperature or refrigeration, the composition includes at least about 70-110% of the amount of cationic cardiolipin (e.g., PCL-2) present when initially formulated. A formulation is considered stable when no more than 10% of the active moiety is lost during the shelf life of the product.

[0031] The liposomal (or other lipid) composition or formulation can be in any desired form. For example, for pharmaceutical use, the composition can be ready for administration to a patient. Where such compositions contain liposomes or other types of lipid vesicles, such formulations typically are in the form of vesicles in an aqueous medium (such as ethanol and water for injection). Alternatively, the formulation can be in dried or lyophilized form, in which instance, the composition preferably includes a cryoprotectant as well. Suitable cryoprotectants include, for example, sugars such as trehalose, maltose, lactose, sucrose, glucose, and dextran, with the most preferred sugars from a performance point of view being trehalose and sucrose. Other more complicated sugars can also be used, such as, for example, aminoglycosides, including streptomycin and dihydrostreptomycin.

[0032] The composition according to the present invention including the inventive cationic cardiolipin can be employed in a variety of applications, such as the *in vivo* or *in vitro* delivery of active agents such as peptides, polypeptides, proteins, nucleotides, polynucleotides, small molecules, or other active agents to human or animal (typically vertebrate) patients, to plants, or to cells in culture. To facilitate such uses, the composition can, in addition to the cationic cardiolipin species, other lipids, and other constituents, further include at least one such active agent. The compositions can be used, for example, in any procedure comprising the use of liposomes or lipid vesicles to deliver substances intracellularly either *in vitro* or *in vivo* (Felgner *et al.* US patent no 5,264,618). The compositions also can be used cosmetically, for example, as a dermatological preparation. Accordingly, the composition can be formulated for use depending on the desired end use.

[0033] A most preferred active agent for inclusion within the inventive composition is a polynucleotide, which can be DNA, RNA, or mixtures of DNA and RNA. Examples of therapeutic polynucleotides include ribozymes, interfering RNA (RNAi) antisense RNA or DNA sequences, which can target desired sequences within cells, such as genes associated with a disease state (e.g., oncogenes or viral genes). Desirably, the polynucleotide for use in the inventive composition hybridizes to a specific human mRNA within cells and further inhibits gene expression as a result of hybridization to the targeted mRNA. For example, the polynucleotide can be targeted to an oncogene such as ras, raf cot, mos, myc, etc., and preferably is targeted to the human c-raf gene. Other preferred genes for targeting with therapeutic ribozymes, interfering RNA (RNAi) antisense RNA or DNA sequences include viral genes, particularly HIV genes, such as the rev transactivator. In other embodiments, a therapeutic polynucleotide can be one which is absent or mutated in a diseased state, or can encode a gene product that is deficient or absent in a diseased state. Other polynucleotides can encode therapeutic polypeptides, such as, for example, immunogenic peptides (which can be used as vaccines), natural hormones, or a synthetic analogue of a natural hormone.

[0034] A preferred polynucleotide for use in the inventive composition is a 5 to 50-mer antisense oligodeoxyribonucleotide, preferably a 10-40-mer sequence, and more preferably a 15-25-mer sequence targeted to a specific gene of interest (see, e.g., U.S. Patent 6,126,965, disclosing a 15-mer anti c-raf-1 oligonucleotide having the sequence 5'-GTGCTCCATTGATGC-3'). Additional suitable anti-raf oligodeoxyribonucleotide sequences are known in the art and can be suitably used in the context of the present invention (see, e.g., U.S. Patents 6,090,626, 6,126,965, 6,333,314, 6,410,518 and international patent application publications WO 94/15645 and 94/23755). Where oligonucleotides are included in the composition, they preferably contain one or more phosphothioate linkages preferably two phosphothioate linkages. Most preferably, oligonucleotides for inclusion in the inventive composition contain one phosphothioate linkage at each terminal end, but they can be present anywhere from one end to the other end (e.g., between the ends) of an oligonucleotide.

[0035] A most preferred composition according to the invention contains a 15-mer anti c-raf-1 oligonucleotide having the sequence 5'-GTGCTCCATTGATGC-3', 1,2-dioleoyl-sn-Glycero-3-Phosphocholine (DOPC), novel positively charged phospholipids 1,3-Bis-(1,2-bis-tetradecyloxy-propyl-3-dimethylethoxyammoniumbromide)-propane-2-ol (PCL-2) and cholesterol as stabilizing agents, D-alpha tocopheryl acid succinate as an antioxidant, sucrose as a tonicity agent and ethanol and water for injection as solvents. This composition can be provided as a sterile liquid containing 2 mg/mL rafAON (50 mg

rafAON per vial).). Each vial is diluted 2-fold with 5% dextrose, USP to yield a 1 mg/mL rafAON liposome formulation. It may be further diluted up to 8-fold with 5% dextrose, USP prior to administration.

[0036] Another preferred polynucleotide for use in the inventive composition is an RNAi species. RNAi technology provides an effective method of suppressing the activity of cellular genes. SiRNA (RNAi) is an RNA molecule having a double-stranded structure (dsRNA) comprising a first complimentary strand and second complimentary strand. The double stranded RNA comprises about 20-26 nucleotides in length, preferably 21 or 23 nucleotides. Each of the first two strands of the dsRNA has a 5' terminus and 3' terminus. Each strand of dsRNA has 1-4 nucleotide hangovers, preferably 2 nucleotides on the 3' terminus. The hangover nucleotides typically comprises thymidine or uridine. Within the siRNA, The first strand of double stranded RNA (dsRNA) comprises nucleotide sequence corresponding at least part of its sequence to the target sequence (e.g., a target mRNA transcript portion of the target gene). The second strand of dsRNA is complimentary to the first strand of dsRNA. Desirably, the target sequence corresponds to an oncogene, such as those discussed herein (preferably c-raf-1), but can be any desired target gene. It is within the ordinary skill in the art to construct a suitable RNAi for targeting a particular gene. Desirably, the dsRNA is produced by chemical synthesis.

[0037] The gene to be targeted with RNAi in accordance with the invention can be selected from any desired species, depending on the desired end application. Thus, for example, the composition can find agricultural use by targeting genes in plants, such as crop plants, or the genes of plant or fungal parasites or pathogens. Similarly, the RNAi can be targeted to animal genes, such as those of pets (e.g., cats, dogs, etc.), common livestock species (e.g., cattle, pigs, sheep, goats, poultry (such as chickens, turkeys, or game fowl), or fur-bearing animals such as mink, sable, fox, and the like. The gene to be targeted also can be of a parasite or pathogen (e.g., bacteria or viral pathogen) of such species.

[0038] The technology also will find medical application by targeting human genes. In a preferred embodiment, the gene to be targeted (e.g., with oligonucleotides or RNAi) is a human or animal oncogene, such as ras, raf cot, mos, myc, and the like. Most preferably, the gene to be targeted is c-raf-1. The sequences of such genes are published, and those of skill in the art are able to construct RNAi that target such genes without undue experimentation. Guidance in this respect is additionally supplied by success in suppressing such genes by antisense RNA and oligonucleotides. Examples of RNAi molecules for use in the context of the present invention include:

Sequence #1

5'-UGGAAUGAGCUUACAUGACdTdT-3'
3'-dTdTACCUUACUCGAAUGUACUG-5'

Sequence #2

5'-GCACGCUUAGAUUGGAACdTdT-3'
3'-dTdTTCGUGCGAAUCUAACCUUGU-5'

Sequence#3

5'-UGCGUCGGAUGCGAGAAUCdTdT-3'
3'-dTdTACGCAGCCUACGCUCUUAG-5'

Sequence #4

5'-UCCGGAUGCAGGAUGACAAdTdT-3'
3'-dTdTAGGCCUACGUCCUACUGUU-5'

Sequence #5

5'-UCAACAGGAGCGCCUCUGAdTdT-3'
3'-dTdTAGUUGUCCUCGCGGAGACU-5'

Sequence #6

5'-UGCUUGCACGCUGACUACAdTdT-3'
3'-dTdTACGAACGUGCGACUGAUGU-5'

Sequence #7

5'-AUUCCUGCUCAAUGGAUUUdTdT-3'
3'-dTdTUAAGGACGAGUUACCUAAA-5'

Sequence #8

5'-GCUGCAUCAAAUGGAGCACAdTdT-3'
3'-dTdTTCGACGUAGUUACCUCGUGU-5'

Sequence #9

5'-CUGCAUCAAAUGGAGCACAUdTdT-3'
3'-dTdTGACGUAGUUACCUCGUGUA-5'

Sequence #10

5'-UGCAUCAAAUGGAGCACAUAdTdT-3'
3'-dTdTACGUAGUUACCUCGUGUAU-5'

Sequence #11

5'-GCAUCAAAUGGAGCACAUACdTdT-3'
3'-dTdTTCGUAGUUACCUCGUGUAUG-5'

Sequence #12

5'-GCUGCAUCAAAUGGAGCACAUU-3'
3'-UUCGACGUAGUUACCUCGUGU-5'

Sequence #13

5'-CUGCAUCAAAUGGAGCACAUUU-3'
3'-UUGACGUAGUUACCUCGUGUA-5'

Sequence #14

5'-UGCAUCAAAUGGAGCACAUUU-3'
3'-UUACGUAGUUACCUCGUGUAU-5'

Sequence #15

5'-GCAUCAAAUGGAGCACAUACUU-3'
3'-UUCGUAGUUACCUCGUGUAUG-5'

Sequence #16

5'-GCUGCAUCAAAUGGAGCACAUAdTdT-3'
3'-dTdTTCGACGUAGUUACCUCGUGUAU-5'

Sequence #17

5'-AAGCUGCAUCAAAUGGAGCACAdTdT-3'
3'-dTdTUUUCGACGUAGUUACCUCGUGU-5'

Sequence #18

5'-GCAUCAAAUGGAGCACAUACAGdTdT-3'
3'-dTdTTCGUAGUUACCUCGUGUAUGUC-5'

Sequence #19

5'-CUGCAUCAAAUGGAGCACAUACdTdT-3'
3'-dTdTGCAGGUAGUUACCUCGUGUAUG-5'

Sequence #20

5'-AAGCUGCAUCAAAUGGAGCACAUACdTdT-3'
3'-dTdTUUUCGACGUAGUUACCUCGUGUAUG-5'

Sequence #21

5'-GCUGCAUCAAAUGGAGCACAUACAGdTdT-3'
3'-dTdTTCGACGUAGUUACCUCGUGUAUGUC-5'

Sequence #22

5'-GCAUCAAAUGGAGCACAUACAGGGAdTdT-3'
3'-dTdTTCGUAGUUACCUCGUGUAUGUCCCU-5'

Sequence #23

5' -UUAAGCUGCAUCAAAUGGAGCACAUdTdT-3'
3' -dTdTAAUUCGACGUAGUUACCUCGUGUA-5'

Sequence #24

5' -GCUGCAUCAAAUGGAGCACAUUU-3'
3' -UUCGACGUAGUUACCUCGUGUAU-5'

Sequence #25

5' -AAGCUGCAUCAAAUGGAGCACAUU-3'
3' -UUUUCGACGUAGUUACCUCGUGU-5'

Sequence #26

5' -GCAUCAAAUGGAGCACAUACAGUU-3'
3' -UUCGUAGUUACCUCGUGUAUGUC-5'

Sequence #27

5' -CUGCAUCAAAUGGAGCACAUACUU-3'
3' -UUGACGUAGUUACCUCGUGUAUG-5'

Sequence #28

5' -AAGCUGCAUCAAAUGGAGCACAUACUU-3'
3' -UUUUCGACGUAGUUACCUCGUGUAUG-5'

Sequence #29

5' -GCUGCAUCAAAUGGAGCACAUACAGUU-3'
3' -UUCGACGUAGUUACCUCGUGUAUGUC-5'

Sequence #30

5' -GCAUCAAUGGAGCACAUACAGGGAUU-3'
3' -UUCGUAGUUACCUCGUGUAUGUCCCU-5'

Sequence #31

5' -UUAAGCUGCAUCAAUGGAGCACAUUU-3'
3' -UUAUUUCGACGUAGUUACCUCGUGUA-5'

[0039] In some embodiments, it is preferred for the composition to comprise a plurality of active agents, such as those identified herein and otherwise known to those of skill in the art. For example, while the inventive composition desirably includes at least one nucleic acid species as noted above (e.g., oligonucleotide, dsRNA, etc.), the composition can include more than one such species. For example, the inventive composition can include a plurality of oligonucleotides, siRNA species, or mixtures thereof. In this respect, in a preferred embodiment, at least two active agents present within the inventive composition comprise nucleic acids. For example, at least one of said nucleic acids can be an siRNA species, an oligonucleotide, or another species of nucleic acid, as desired. Where a nucleic acid targets a gene sequence (e.g., for inhibition, such as RNAi or antisense oligonucleotide inhibition), a first and a second nucleic acid species present in the composition can be designed to target separate genetic sequences. Such separate target sequences can be found in separate genes, which can facilitate inhibiting multiple genes in target cells. Alternately or in addition, the separate target sequences can be found in the same gene. In such embodiments, the combined effect of the different species of inhibiting nucleic acids in the composition can enhance the ability to reduce expression of the target gene.

[0040] Desirably, where polynucleotides are included within the inventive composition, the respective charge ratio of cationic lipid: polynucleotide (e.g., oligodeoxyribonucleotide, RNAi, etc.) ranges from (1-4):1, such as between 2:1 and 3:1. Because PCL-2 has two positive charges, the overall lipid:drug molar amounts can be lower in the present invention than in previously reported cationic liposomal formulations. Desirably the respective total lipids to polynucleotide (e.g., oligodeoxyribonucleotide, RNAi, etc.) molar amounts are between about 10:1 and about 200:1, such as between about 20:1 and about 150:1 or between about 50:1 and about 100:1. Where the composition is liposomal, desirably at least about 40%, and more desirably at least about 50%, of the polynucleotide (e.g., oligodeoxyribonucleotide, RNAi, etc.) is complexed with cationic lipids in the inner core of

the liposomes. Typically, between about 60% and about 80% of the polynucleotide (e.g., oligodeoxyribonucleotide, RNAi, etc.) is complexed with cationic lipids in the inner core of the liposomes and between about 40% and about 20% of the polynucleotide (e.g., oligodeoxyribonucleotide, RNAi, etc.) is on the outer surface of the membrane. However, in some embodiments, more (e.g., about 90% or even about 95%) of the polynucleotide (e.g., oligodeoxyribonucleotide, RNAi, etc.) can be complexed with cationic lipids in the inner core of the liposomes. The high intraliposomal entrapment imparts sustained release of c-rafAON from the formulation.

[0041] Where the polynucleotide (e.g., RNAi or oligonucleotide) within the composition targets an oncogene, the invention provides a method of inhibiting the growth of neoplastic cells using such a composition. In accordance with the inventive method, the composition is administered to such cells under conditions for the polynucleotide (e.g., RNAi or oligonucleotide) to enter the cells. Within the cells, the polynucleotide (e.g., RNAi or oligonucleotide) inhibits the activity of the oncogene to which it is targeted, which results in the inhibition of growth of such neoplastic cells. In this context, "inhibition" does not require a complete cessation of the growth or proliferation of such cells. It is sufficient for the method to retard neoplastic growth. However, it is desirable for the proliferation of the neoplastic cells to be substantially reduced or even eliminated.

[0042] When used against neoplastic cells, the method can be employed to cells *in vivo* or *in vitro*. For *in vitro* applications, the method can be used in research, e.g., to study neoplastic growth and proliferation. *In vitro* applications also can find use in developing therapies based on the inventive method. For such applications, the composition can be added to the culture medium of the cells or used in a similar manner as common lipid-based transfection agents (e.g., LIPOFECTIN®).

[0043] When used *in vivo*, the inventive method can be employed to treat a patient suffering from infectious diseases (e.g., bacterial infections, viral infections, etc.), autoimmune diseases (e.g., and cancer. Preferably, in such an embodiment, the composition comprising the cationic cardiolipin analogue and the polynucleotide (e.g., RNAi or oligonucleotide) targeting an oncogene is delivered to the patient under conditions sufficient for the polynucleotide (e.g., RNAi or oligonucleotide) to enter neoplastic cells in the patient. Within the cells, the polynucleotide (e.g., RNAi or oligonucleotide) inhibits the expression or activity of the oncogene, which results in an inhibition of the growth of the neoplastic cells within the patient. The cells can be, for example, cancer cells and can be within a tumor or metastasized.

[0044] As noted above, it is sufficient for the inventive method to retard the growth or proliferation of such cells. It is not a requirement that the inventive method completely eliminate neoplastic cells from the patient. Rather, it is sufficient for the inventive method to retard the growth or proliferation of the neoplastic cells within the patient. Preferably, the inventive method substantially inhibits the growth of the neoplastic cells, and, in some embodiments, the inventive method can result in tumor regression or elimination of neoplastic cells from the patient.

[0045] In accordance with the inventive method, the composition comprising the polynucleotide can be employed adjunctively with a second antineoplastic agent. Such a second antineoplastic agent can be, for example, a chemotherapeutic agent, a source of radiation, a gene therapy vector, or other antineoplastic agent. Specific examples of such chemotherapeutics include camptothecins (e.g., SN-38, irinotecan, etc.), doxorubicin, daunorubicin, methotrexate, adriamycin, tamoxifen, toremifene, cisplatin, epirubicin, docetaxal, paclitaxal, Gemzar, gemcitabine HCl, mixotrantrone, and other known chemotherapeutics useful for treatment of cancer. When used adjunctively, the inventive composition comprising can be delivered prior to, concurrently with, or after the second antineoplastic agent. However employed, the inventive composition can enhance the efficacy of the second antineoplastic agent. Thus, the invention can be used to chemosensitize a tumor to the effect of chemotherapy. Similarly, the invention can be used to radiosensitize a tumor to the effects of radiation. In this respect, it is sufficient for the inventive method involving the use of a composition including the cationic cardiolipin analogue and the polynucleotide (e.g., RNAi or oligonucleotide) to contribute to the efficacy of the combined treatment regimen.

[0046] In another embodiment, the invention provides a method for validating a target for genetic inhibition. In accordance with this aspect of the invention, the inventive composition comprising a polynucleotide targeted to a particular gene is administered to cells expressing a target gene of interest under conditions for the polynucleotide (e.g., RNAi or oligonucleotide) to enter the cells. Within the cells, the polynucleotide (e.g., RNAi or oligonucleotide) inhibits the activity of the gene to which it is targeted. Thereafter, the effects of the inhibition of the gene are assayed.

[0047] The method of validating the target for genetic inhibition can be practiced using cells *in vitro* or *in vivo*, depending on the nature of the inquiry. The assay conducted to assess the effects of inhibition of the target gene can be qualitative – such as by probing for the presence or level of the targeted gene RNA or the expressed protein. In this sense, a

reduction in the level of the targeted gene RNA or a reduction in the expression of the encoded protein of interest can serve to validate the target of the oligonucleotide, RNAi, or other inhibitor of gene expression. Alternative assays can be behavioral or phenotypic. For example, the composition can be administered to an animal or to a tissue within the animal, and the animal monitored to assess a behavioral or phenotypic change. In this sense, for example, genes mediating appetite can be validated by administering to an animal a composition comprising a genetic inhibitor of the putative appetite-regulating gene and observing the effect of the inhibition on the animal's appetite. A positive correlation between inhibition of the gene expression and a behavioral change in the animal can serve as a validation of the target. This method can rapidly identify and validate targets for therapeutic intervention. Traditionally, validation methods are costly and time-consuming, for example, requiring the generation of animal models, such as knock-out animals. The inventive method, in contrast, can much more rapidly and easily inhibit the expression of a putative target gene in a cell or an animal, which can accelerate and simplify the process of target validation.

[0048] Where the composition includes a fluorescent or luminescent cardiolipin analogues (or any other fluorescent or luminescent moiety), the invention provides a method of tracking the migration of the composition within an animal, plant, or other desired system. In accordance with this aspect of the invention, a composition of the present invention including the fluorescent or luminescence moieties is introduced into the animal, plant, or other desired system. Immediately upon introduction or after a desired passage of time, the fluorescence or luminescence can be monitored by exposure to light, X-rays, or other ionizing radiation. This can be measured either through real-time observation or photographic detection. The method can be used to mark the migration of the lipid composition within the animal, plant, or other desired system. The method can serve to identify sites to which the lipid composition is concentrated, for example. This can serve to assess the effectiveness of a targeting moiety, if one is present in the composition. Additionally, the method can assist in determining the local concentration of the composition within an animal, plant, or other desired system. The local lipid concentration can also be detected by taking an organ tissue of interest or blood sample and treating with suitable chemical before the fluorescence or luminescence. Such information can be useful in designing and evaluating therapies wherein the local concentration of a therapeutic composition is of interest.

[0049] Of course, the method can be employed repeatedly. In this sense, after the initial detection of fluorescence, the moiety is again caused to fluoresce and the fluorescence again

detected. This can serve to identify the change in position over time of the composition. Such information can be used to track the progression of tissues into which the composition may become concentrated, the migration of certain cell types. Alternatively, the method can help monitor the clearance of the composition from the animal, plant, or other desired system. Both fluorescence and luminescence methods can be useful depending on the application. Luminescence application may include studies requiring greater decay time such as effective monitoring of lateral diffusion of lipids across the membrane.

[0050] In another aspect, the invention entails the use of the compositions described herein as transfection agents. Thus, the composition can be admixed with a desired species or library of polynucleotide(s) and delivered to cells. The compositions of the present invention comprises desired polynucleotides, and the invention provides a method of transfecting cells with such polynucleotides by exposing the desired cell (or cells) to the composition under conditions sufficient for the polynucleotide to enter the cell(s) both *in vivo* or *in vitro*. For *in vitro* applications, the composition can be added to the culture medium of the cells or used in a similar fashion as common lipid-based transfection agents (e.g., LIPOFECTIN®). A desired quality of the present compositions, comprising cationic cardiolipin (especially PCL-2) is that they can serve as effective transfection agents even for primary cultures, whereas commonly employed transfection agents are generally ineffective in primary cultures. Moreover, the method of transfecting cells using the inventive composition can be employed *in vivo*. As noted herein the method can be use to deliver polynucleotides that target specific genes, notably oncogenes. However, the method can be used to transfect cells *in vivo* with any desired polynucleotide. An advantage to employing the inventive compositions for this purpose is that the polynucleotide of interest can be delivered to cells without substantial toxicity, for example as is observed with LIPOFECTIN® and other lipid transfection agents. Thus, the invention provides a transfection agent that can be employed *in vivo* and *in vitro*, including primary and transformed cells.

[0051] Many aspects of the invention involve delivery of the composition to an animal, such as a veterinary patient or human. For delivery to a patient, the composition can be supplied in any suitable manner. For delivery to a tumor, for example, the composition can be formulated for injection directly into the tumor mass or infused through the circulation in the tumor. Alternatively, the composition can be delivered by injection (e.g., parenteral, intravenous, etc.) or adsorption (e.g., transdermal, transmucosal), as desired. Dermatological preparations can be applied suitable to skin or mucous tissues.

[0052] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

EXAMPLE 1

[0053] This example demonstrates the construction of nine PCL-2-based cationic liposomes for gene transfer. These formulations are suitable for mixing with any polynucleotide of choice for evaluating transfection efficiency.

[0054] Cationic cardiolipin, PCL-2, and either DOPE or Cholesterol quantities corresponding each formulation (indicated in table 1A) were dissolved in chloroform in a round bottom flask. The solvent was removed under reduced pressure using a rotary evaporator to form a lipid film. The lipid film was further dried under vacuum overnight, and then hydrated with 20 mM HEPES buffer (pH 7.3), under nitrogen, at 25 – 40 °C. The bulk cationic liposomes were extruded through 0.2 µm pore size polycarbonate filter three times, and 0.1 µm pore size polycarbonate filter five times. The extruded cationic liposomes were characterized by size and pH (see the following table).

Table 1A

Formulation Lot #	Molar Ratio		Lipid Concentration		Liposome Size (nm)		pH
	PCL-2/CHOL	PCL-2/DOPE	PCL-2 (mM)	Total Lipids (mg/mL)	Mean	D99	
PDM-GT-03-001	1 : 1		10	17.14	144.2	259.4	7.54
PDM-GT-03-002	3 : 2		10	15.85	173.8	290.2	7.45
PDM-GT-03-003	2 : 3		10	19.07	128.5	230.0	7.44
PDM-GT-03-004	2 : 1		10	15.20	163.3	311.4	7.64
PDM-GT-03-005		1 : 1	10	20.71	105.7	211.7	7.37
PDM-GT-03-006		2 : 1	10	16.99	101.6	182.0	7.28
PDM-GT-03-007		1 : 2	10	28.15	114.8	208.7	7.32
PDM-GT-03-008		3 : 2	10	18.23	109.2	196.0	7.46
PDM-GT-03-009		2 : 3	10	24.43	117.5	219.9	7.29

EXAMPLE 2

[0055] This example demonstrates the construction of a PCL-2-based cationic liposome composition containing an antisense oligodeoxyribonucleotide

[0056] The composition is in the form of a lamellar complex having a percent molar ratio of 1,2 Dioleoyl-sn-glycero-3-phosphocholine (DOPC):cholesterol: and 1,3-Bis-(1,2-bistetradecyloxy-propyl-3-dimethylethoxyammonium bromide)-propane-2-ol (PCL-2), of 55:27:17 and having complexed therein c-rafAON (sequence sequence 5'-GTGCTCCATTGATGC-3') at total lipids:c-rafAON ratio of 90:1 and PCL-2:c-rafAON charge ratio of 2.2:1. This formulation also contains D-alpha tocopheryl acid succinate at 0.2 wt % and sucrose at 10-12 wt %.

[0057] c-rafAON (Lot ALH-01J-003-M) was obtained from Avecia Laboratories (MA, USA). DOPC, cholesterol, alpha tocopheryl acid succinate were obtained from Avanti Polar Lipids (Alabaster, AL, USA). PCL-2 was synthesized at NeoPharm Inc. Sucrose was obtained from Mallinckrodt (St. Louis, MO, USA).

[0058] To form this composition, the lamellar complex formulations were prepared by the thin film hydration method. The lipids (DOPC, PCL-2, cholesterol and D-alpha tocopheryl acid succinate) were dissolved in dehydrated alcohol. The lipid solution was evaporated to dryness using a rotary evaporator. After evaporation, the lipid residue was further dried overnight in a dessicator. Sucrose and c-raf AON were dissolved in de-ionized water. Then, the dried lipid residue was hydrated in the c-raf AON/sucrose solution to form a homogenous suspension. The size of the particles in the suspension was further reduced by extrusion through 0.8, 0.4, 0.2 and 0.1µm sized polycarbonate filters. The prototypes can also be prepared by reverse phase evaporation and ethanol injection methods.

[0059] The morphology of the formulation was determined by freeze-fracture microscopic method. Briefly, samples were quenched using sandwich technique and liquid nitrogen cooled propane at a cooling rate of 10,000 kelvin/second. The fracturing process was carried out in JEOL JED-9000 freeze-etching equipment and the exposed fracture planes were shadowed with platinum for 30 sec in an angle of 25-35 degree and with carbon for 35 sec (kV/60-70mA, 1/10-5 Torr). The platinum replicas were cleaned with concentrated, fuming HNO₃ for 24 to 36 hours, followed by repeating agitation with fresh chloroform/methanol (1:1 by volume) for at least five times. Subsequently, these cleaned replicas were examined with a JEOL 100 CX electron microscope.

[0060] The stability of the formulation was evaluated after storage at 2-8 °C and 25 °C for one month. The particle of the lamellar complex formulations was measured by dynamic light scattering technique (Nicomp Particle Sizer). The drug entrapment efficiency of the formulation was determined by ultrafiltration and/or passage through Centricon filters

with 100,000 molecular weight cut off. The free and entrapped drug and lipid contents were determined by HPLC methods.

[0061] The freeze-fracture replicas revealed complexes of unilamellar liposomes of mean size of about 50-200 nm. The c-rafAON formulation stored at 2-8 °C or 25 °C was stable for one month. The mean particle size, entrapment efficiency, c-rafAON and DOPC concentrations were not significantly different from initial values after 1 month storage at 2-8 °C and 25 °C. These results are presented in Figure 2A and Table 2.

Table 2: One Month Stability data for GMP batch

Test	Specification	Initial	Storage Conditions	
			5°C (inverted)	25°C/60%RH (inverted)
Appearance	White Suspension	Conforms	Conforms	Conforms
pH	Report	5.0	5.1	5.0
rafAON	90-110%	107%	102.5%	103.0%
DOPC	70-110%	92.2%	93.8%	93.1%
Cholesterol	70-110%	93.5%	94.9%	94.7%
PCL-2	70-110%	87.1%	89.3%	90.8%
Mean Particle Size	< 400 nm	138.6nm	135.7nm	135.1nm
rafAON Entrapment Efficiency	> 85%	100%	100.0%	100.0%




Figure 2A

EXAMPLE 3

[0062] This example demonstrates the construction of a PCL-2-based cationic liposome composition containing an antisense oligodeoxyribonucleotide.

[0063] The composition is a lamellar complex having a percent molar ratio of 1,2 Dioleoyl-sn-glycero-3-phosphocholine (DOPC):1cholesterol: and 3-Bis-(1,2-bistetradecyloxy-propyl-3-dimethylethoxyammonium bromide)-propane-2-ol (PCL-2, of 60:31:9 and having complexed therein c-rafAON at total lipids:c-rafAON ratio of 195:1 and PCL-2:c-rafAON charge ratio of 2.4:1. This formulation also contains D-alpha tocopheryl acid succinate at 0.2 wt % and sucrose at 10 wt %.

[0064] c-rafAON (Lot ALH-01J-003-M) was obtained from Avecia Laboratories (MA, USA). DOPC and cholesterol were obtained from Avanti Polar Lipids (Alabaster, AL,

USA) and alpha tocopheryl acid succinate from Sigma. PCL-2 was synthesized at NeoPharm Inc. Sucrose was obtained from Mallinckrodt (St. Lois, MO, USA).

[0065] The lamellar complex formulations were prepared by the thin film hydration method. The lipids (DOPC, PCL-2, cholesterol and D-Alpha Tocopheryl acid Succinate) were dissolved in dehydrated alcohol. Sucrose and c-raf AON were dissolved in de-ionized water. With constant stirring, the lipid solution was added to the c-rafAON solution to form multilamellar complexes. The size of the particles in the suspension was further reduced by extrusion through 0.8, 0.4, 0.2 and 0.1 μm sized polycarbonate filters. The particle of the lamellar complex formulations was measured by dynamic light scattering technique (Nicomp Particle Sizer). The drug entrapment efficiency was determined by ultrafiltration and/or pass through Centricon filters with 100,000 molecular weight cut off, followed by the analysis of free c-rafAON in the filtrate by a HPLC method.

[0066] The release of c-rafAON from the lamellar complex formulation was determined by a reverse dialysis method. Briefly, 20 mL aliquot of the formulation was placed into 180 mL of stirred Phosphate Buffered Saline (PBS), pH 7.4 buffer, in which dialysis membrane tube (10,000 MW cutoff) containing 2 mL of the same PBS buffer was previously placed. At various time intervals, one dialysis tube is removed and analyzed for c-rafAON concentration.

[0067] The stability of the formulation was evaluated after storage at 2-8 °C for two months. The particle of the lamellar complex formulations was measured by dynamic light scattering technique (Nicomp Particle Sizer). The drug entrapment efficiency of the formulation was determined by ultrafiltration and/or passage through Centricon filters with 100,000 molecular weight cut off. The free and entrapped drug and lipid contents were determined by HPLC methods. It was observed that the lamellar complex formulation stored at 2-8 °C was stable for two months. The mean particle size, entrapment efficiency, c-rafAON and DOPC concentrations were not significantly different from initial values after 2 months of storage at 2-8°C. These results are presented in Tables 3A and 3B:

Table 3A. Stability of lamellar complex formulation of c-rafAON

TIME (Month)	Storage conditions	Particle size (nm)		Entrapment Efficiency (%)
		Mean	99 percentile <	
Initial		162	294	98.8
2 month	2-8°C	162	287	98.7

Table 3B. Stability of lamellar complex formulation of c-rafAON

TIME (month)	Storage conditions	c-raf AON (% of initial concentration)	DOPC (% of initial concentration)	PCL-2 (% of initial concentration)
Initial		100	100	100
2 month	2-8°C	96	98	97

[0068] The physical and chemical stability of 8-fold diluted formulation samples in 5% Dextrose Solution was evaluated after storage at room and refrigerated temperatures (2-8 °C) for up to 48 hours. All stability samples were analyzed for appearance, pH, particle size, c-rafAON entrapment efficiency, c-rafAON concentration, DOPC concentration, cholesterol concentration and PCL2 concentration. The mean vesicle size was approximately 200 nm and entrapment efficiency of >99%. Less than 20 percent of c-rafAON was released from the formulation after 72 hours of dialysis. As presented in Table 3C, c-rafAON, DOPC, PCL-2, Cholesterol assay values, entrapment efficiency, pH and mean vesicle size were not significantly different from initial values after storage at 2-8°C or room temperature for 48 hours. The preparations were diluted in 5% Dextrose, USP.

Table 3C: Results of Liposomal rafAON (LErafAON) 8-fold diluted with 5% dextrose solution

Test	Initial	2-8 °C			Room Temperature		
		8 hr	24 hr	48 hr	8 hr	24 hr	48 hr
Appearance	White translucent suspension	White translucent suspension	White translucent suspension	White translucent suspension	White translucent suspension	White translucent suspension	White translucent suspension
pH	4.88	4.98	4.88	4.86	4.90	4.79	4.82
rafAON (mg/mL)	0.25 (100.0%)	0.23 (92.4%)	0.25 (101.0%)	0.24 (97.2%)	0.24 (97.2%)	0.24 (95.6%)	0.25 (100.0%)
DOPC (mg/mL)	2.02 (95.1%)	2.00 (94.0%)	2.01 (94.4%)	2.30 (108.0%)	1.93 (90.8%)	2.27 (107.0%)	2.26 (106.3%)
Cholesterol (mg/mL)	0.49 (97.0%)	0.47 (94.0%)	0.49 (98.8%)	0.53 (105.0%)	0.46 (92.6%)	0.53 (105.4%)	0.53 (105.2%)
(R)-PCL2 (mg/mL)	1.08 (96.1%)	1.07 (94.8%)	1.11 (99.0%)	1.02 (90.7%)	1.17 (103.8%)	1.17 (103.8%)	0.99 (87.6%)
Liposome Mean Size (D99)	150.1 nm (274.9)	145.8 nm (257.5)	147.4 nm (258.5)	144.6 nm (257.3)	147.5 nm (251.4)	147.6 nm (258.2)	148.1 nm (254.1)
Entrapment Efficiency (%)	100%	100%	100%	100%	100%	100%	100%

EXAMPLE 4

[0069] This example demonstrates the *in vivo* efficacy and low toxicity of a composition according to the present invention containing a c-raf-1 antisense oligonucleotide as compared to other liposomal antisense oligonucleotide formulations.

Formulations

[0070] The test formulation (LErafAON-ETU) as prepared as described in Figure 1. Briefly, the lipid excipients, namely, DOPC, cholesterol, PCL-2 and D-Alpha tocopheryl acid succinate were dissolved in dehydrated ethanol and ii) the active ingredient a c-raf-1 antisense oligonucleotide (having the sequence 5'-GTGCTCCATTGATGC-3') and sucrose were dissolved in sterile water for injection. Ethanolic lipid solution was added to aqueous active solution to form liposomes. Following QS to batch weight, liposomes were extruded

to meet size specifications and the ethanol was removed by rotary evaporation. After adjusting the batch weight to pre-solvent removal weight, the product was filtered through 0.22 μ sterilizing filter and filled in sterile vials, stoppered and sealed.

[0071] The comparator formulation (DDAB-LeraFAON formulation) contained the same concentration of antisense oligonucleotide but was formulated using commercially available cationic lipid, dimethyldioctadecyl ammonium bromide (DDAB).

[0072] The manufacturing process for non-sonicated 2-vial LeraFAON formulation involved separate batch preparations of lyophilized lipids and rafaON. For lyophilized lipids, lipid excipients, namely, Egg Phosphatidylcholine (Egg PC), Cholesterol and DimethylDodecylAmmonium Bromide (DDAB) was first dissolved in tertiary butyl alcohol, the solution was filtered through 0.22 μ m sterilizing filter, filled into sterile vials and lyophilized. Lyophilized rafaON was manufactured by dissolving the drug substance in sterile water for injection, followed by its filtration through 0.22 μ m sterilizing filter, filling in sterile vials and lyophilization. Immediately prior to administration, the rafaON lyophilized vial is reconstituted with 0.9% Sodium Chloride, USP. The reconstituted rafaON is then transferred into a vial of lyophilized lipids, hydrated and sonicated for 10 minutes.

Pharmacology Studies

[0073] The *in vivo* efficacy of the PCL-2 formulation, LeraFAON-ETU, was compared to that of the DDAB formulation, LeraFAON, in four studies.

1. *In Vivo* Efficacy of LeraFAON-ETU and LeraFAON in SCID Mice Bearing Human Prostate (PC-3) Tumors

[0074] The multiple dose therapeutic efficacies of the PCL-2 formulation LeraFAON-ETU, and the control formulation, LeraFAON, were evaluated in a SCID mouse xenograft model of human prostate cancer. PC-3 cells in the logarithmic growth phase were implanted subcutaneously (s.c.) in C.B.-17 SCID mice. Animals bearing tumors (50-125 mm³) were randomized into different treatment groups (5-7 mice/group), and mice received iv administration of control vehicle, LeraFAON at 12.5 or 25 mg/kg/day, or LeraFAON-ETU at 12.5 or 25 mg/kg/day, on Days 1, 2, 4, 5, 7, 8, 10, 11, 13 and 14. Efficacy was evaluated by comparing the % initial tumor volume (where Day 1 = 100%) of controls with LeraFAON and LeraFAON-ETU groups on Day 20.

[0075] Animals treated with 12.5 mg/kg/day of LerafaON or LerafaON-ETU did not show any tumor growth inhibition. However, animals treated with LerafaON or LerafaON-ETU at 25 mg/kg/day exhibited 15% and 44% tumor growth inhibition, respectively, compared to their respective controls (10% Sucrose). Both LerafaON and LerafaON-ETU were well tolerated, as no differences in body weight loss were observed.

[0076] The results of this study suggest that overall both the PCL-2 formulation (LerafaON-ETU) and the DDAB liposomal formulation (LerafaON) had comparable therapeutic efficacy against the human prostate tumor model in SCID mice.

2. *In Vivo* Efficacy of LerafaON-ETU and LerafaON in SCID Mice Bearing Human Breast (MDA-MB-231) Tumors

[0077] The multiple dose therapeutic efficacies of the PCL-2 formulation, LerafaON-ETU and the control formulation, LerafaON, were evaluated in a SCID mouse xenograft model of human breast cancer. MDA-MB-231 cells in the logarithmic growth phase were implanted s.c. in C.B.-17 female SCID mice. Animals bearing tumors (50-100 mm³) were randomized into different treatment groups (8 mice/group), and received iv administration of control vehicle, or 25 mg/kg/day LerafaON or LerafaON-ETU on Days 1, 2, 4, 5, 7, 8, 10, 11, 13 and 14.

[0078] Maximal tumor growth inhibition was 65% on Day 12 and 59% on Day 15 for LerafaON and LerafaON-ETU, respectively, compared to the appropriate vehicle controls. No body weight loss was observed for any of the treatment groups.

[0079] The results suggest that LerafaON-ETU has equivalent therapeutic efficacy against the MDA-MB-231 human breast cancer tumor model as compared to the control LerafaON formulation.

3. *In Vivo* Efficacy of LerafaON-ETU and LerafaON and Their Combinations With Taxol® in SCID Mice Bearing Human Ovarian (SKOV-3) Tumors

[0080] A multiple dose therapeutic efficacy study of LerafaON-ETU and LerafaON alone and in combination with Taxol® was conducted in a SCID mouse xenograft model of human ovarian cancer. SKOV-3 cells in the logarithmic growth phase were implanted s.c. in C.B.-17 SCID mice. Treatment with controls or test articles was initiated when tumor volume reached 50-100 mm³. Mice were randomized into treatment groups with 5-7 animals per group, then dosed intravenously with vehicle controls or with 25 mg/kg/day

LErafAON or LErafAON-ETU on Days 1, 2, 4, 5, 7, 8, 10, 11, 12, and 13. Taxol® (25 mg/kg) was also administered intravenously to designated groups on Days 2, 5, and 9. Animals from combination therapy groups received Taxol® 2-3 hours after receiving the respective liposome formulation of rafAON.

[0081] LErafAON and LErafAON-ETU showed maximum tumor growth inhibition on Day 23 of 38% and 45%, respectively. Taxol® exhibited maximal tumor growth inhibition of 41% on Day 19. The combinations of Taxol® + LErafAON or Taxol® + LErafAON-ETU significantly regressed tumor growth by 90%. In addition, tumor growth to volumes greater than 400 mm³ was delayed 13 days by Taxol® + LErafAON and 24 days by Taxol® + LErafAON-ETU.

[0082] The results of this study indicate that the PCL-2 formulation LErafAON-ETU has equivalent therapeutic efficacy as the control LErafAON against the SKOV-3 human ovarian cancer tumor model in SCID mice when administered as a single agent. However, in combination treatment with Taxol®, the PCL-2 formulation, LErafAON-ETU, resulted in superior tumor growth delay compared to the DDAB formulation (LErafAON).

4. *In Vivo* Efficacy of LErafAON-ETU and LErafAON and Their Combinations with Taxotere® in SCID Mice Bearing Human Prostate (PC-3) Tumors

[0083] A multiple dose therapeutic efficacy study of the PCL-2 formulation, LErafAON-ETU, and the control DDAB formulation, LErafAON, alone and in combination with sub-therapeutic doses of Taxotere® was conducted in a SCID mouse xenograft model of human prostate cancer. PC-3 cells in the logarithmic growth phase were implanted s.c. in C.B.-17 SCID mice. Animals bearing tumors (50-100 mm³) were randomized into different treatment groups (5-7 mice/group), and controls or test articles (25 mg/kg/day LErafAON or LErafAON-ETU) were administered intravenously for 5 consecutive days. Taxotere® was dosed to designated groups at 10 mg/kg on Day 2 and 5 mg/kg on Day 5. Efficacy was evaluated by comparing the % initial tumor volume (where Day 1 = 100%) of controls with treated groups on Day 21.

[0084] Tumor growth was inhibited 7% and 40% for mice dosed with LErafAON and LErafAON-ETU, respectively, compared to their controls. Taxotere® alone resulted in 83% tumor growth inhibition, whereas, in combination treatment, LErafAON + Taxotere® led to a similar tumor growth inhibition of 81%. Animals dosed with the PCL-2

formulation, LerafaON-ETU, + Taxotere® showed 99% tumor growth inhibition on Day 21. These results are presented in Figures 4A and 4B.

[0085] The results of this study suggest that the PCL-2 formulation, LerafaON-ETU, in combination with Taxotere® has greater therapeutic efficacy in comparison to the control DDAB formulation LerafaON + Taxotere® combination.

Pharmacokinetics

[0086] The pharmacokinetics of the PCL-2 rafaON formulation, LerafaON-ETU, was compared to that of the control (DDAB) liposome formulation, LerafaON, in CD2F1 mice.

1. Bioanalytical Methods

[0087] Bioanalytical methods were developed to quantify total rafaON in mouse plasma and mouse tissues containing LerafaON or LerafaON-ETU, and were used to quantify rafaON in plasma and tissue samples from the single dose pharmacokinetics and tissue distribution study in mice. RafaON was extracted from mouse plasma samples by solid phase extraction (SPE), then quantified using LC-MS/MS. The method was found to be linear over the range 25-5000 ng/mL in mouse plasma. Tissues were homogenized mechanically to form a 5% (w/v) homogenate; this was then subjected to protein precipitation for sample preparation. Total rafaON was then quantified in samples by an LC-MS/MS method with linearity from 50-10,000 ng/mL tissue homogenate.

2. Pharmacokinetics and Tissue Distribution Study of LerafaON-ETU and LerafaON in Mice

[0088] A single dose pharmacokinetics and tissue distribution study of the control LerafaON and the PCL-2 formulation (LerafaON-ETU) was conducted following a 30 mg/kg intravenous dose to male CD2F1 mice. Three mice/group/time points were sacrificed at 5, 15 and 30 minutes and at 1, 2, 4, 8, 24, and 48 hours after formulation administration. Blood samples were processed for plasma, and plasma and tissues were assayed for rafaON concentrations.

[0089] The plasma C_{max} for animals dosed with LerafaON-ETU was approximately twice that for animals dosed with LerafaON. Total exposure (AUC_{0-48h} and $AUC_{0-\infty}$) was 2.3-fold higher for LerafaON-ETU than for LerafaON dosed mice. Clearance of LerafaON was 2.5-fold faster and volume of distribution (V_z) was almost 4-fold greater than for LerafaON-ETU.

[0090] RafAON was rapidly distributed to the tissues following dose administration. The order of increasing tissue exposure over 48 hours was lungs > spleen > liver > kidneys > heart, for both formulations. RafAON concentrations were found to be greater in mice dosed with the PCL-2 formulation (LErafAON-ETU) in comparison to the DDAB formulation (LErafAON).

Toxicology

[0091] The toxicity of the PCL-2 rafAON formulation, LErafAON-ETU, was compared to that of the control liposome formulation, LErafAON, in CD2F1 mice.

Multiple Dose Toxicity in Mice

[0092] A comparative multiple dose toxicity study of the control (LErafAON) and the PCL-2 formulation (LErafAON-ETU) was conducted in male and female CD2F1 mice. Animals were randomized into treatment groups (10/sex/group) and were dosed intravenously with 35 mg/kg/day LErafAON or LErafAON-ETU for 5 consecutive days.

[0093] No significant body weight loss or clinical signs of toxicity were observed in mice dosed with the PCL-2 formulation (LErafAON-ETU). The mortality of animals dosed with LErafAON-ETU was 0% for both males and females, and was 100% for males and 40% for females dosed with LErafAON. All males and 40% of the females dosed with LErafAON were found dead by Day 5, and all showed clinical signs of toxicity (hunched posture, rough coats, and dehydration). No statistically significant body weight loss was observed in the males, however females had 12% weight loss on Day 8, but recovered by Day 17. The females that survived dosing with LErafAON beyond Day 5 were lethargic, but recovered by Day 9. The results of this study are presented in Figure 4C.

[0094] Histopathological evaluations concluded that the mortality of mice dosed with LErafAON was caused by pulmonary hemorrhage. Lesions were observed in the spleen, lungs, and liver of mice dosed with LErafAON, but not in mice dosed with the PCL-2 formulation (LErafAON-ETU). Clinical pathology tests showed no significant differences in clinical chemistry between mice dosed with controls and those dosed with LErafAON or LErafAON-ETU.

[0095] The results of this study indicate that the PCL-2 formulation (LErafAON-ETU) is less toxic to CD2F1 mice than the control formulation LErafAON.

EXAMPLE 5

[0096] This example demonstrates the transfection efficiency of the inventive composition in transfecting cells. The example highlights the ability of the PCL-2 formulation to transfect a variety of cell lines including primary cells, and the results reveal that the inventive composition can mediate transfection of cells more efficiently in cell lines tested than commonly employed transfection reagents, such as LIPOFECTIN® and Lipofectamine 2000™.

[0097] The composition for use in the experiments reported in this example (referred to herein as “NeoPhectin™”) was prepared using procedure described in Example 1. The inventive formulation contained PCL-2 and DOPE.

1. Transfection Efficiency in CHO Cells

[0098] NeoPhectin™ was evaluated for transfection in Chinese hamster ovary (CHO) cells using CMV-luciferase reporter gene plasmid and compared with LIPOFECTIN®. One µg DNA was added to CHO cells in the presence and absence of NeoPhectin™ or LIPOFECTIN® in a 24 well plate. Cells were incubated for 4h in serum-free medium, then changed to medium containing 10% serum for further 24h. Protein concentration was measured by the bicinchoninic acid (BCA) protein assay using bovine serum albumin as a standard, and transfection efficiency was determined by measuring relative light units/mg of cell protein. The results of this experiment (see Figure 5A) indicate that at all concentrations NeoPhectin™ exhibited significantly greater transfection efficiency than LIPOFECTIN®.




Figure 5A – Transfection Efficiency of NeoPhectin™ in CHO cells

2. Transfection Efficiency in COS-1 Cells

[0099] NeoPhectin™ was evaluated for transfection in COS-1 cells using LacZ plasmid. Four µg of plasmid pcDNA3.1/His/LacZ was incubated with NeoPhectin™ or LIPOFECTIN® in serum free media at room temperature for 30 min. Subsequently, reagent mixture was added to 0.3 million cells per well and incubated for 6 h in serum free medium. The mixture was replaced with 10% serum media and further incubated for 48h. The transfection efficiency was measured by staining with β-Gal staining kit and counting number of cells transfected per field using inverted microscope. The results of this experiment (see Figure 5B) indicate that at all concentrations, NeoPhectin™ exhibited significantly greater transfection efficiency than LIPOFECTIN®.




Figure 5B – Transfection Efficiency of the NeoPhectin[™] in COS-1 cells

3. NeoPhectin[™] Mediated Delivery of RNAi in Primary Rat Lung Microvessel Endothelial Cells (RLMVEC)

[00100] NeoPhectin[™] was evaluated for delivery of RNAi in primary rat lung microvessel endothelial cells (RLMVEC). RNAi was admixed with NeoPhectin[™] and various concentrations were exposed to RLMVEC (see Figure 5C). The efficiency of transfection was assessed by measuring the uptake of the RNAi oligos in relative units. The results of this experiment (see Figure 5C) indicate that NeoPhectin[™] efficiently delivered RNAi to the RLMVEC.




Figure 5C - NeoPhectin™ Mediated Delivery of RNAi in Primary Rat Lung Microvessel Endothelial Cells (RLMVEC)

4. Transfection Efficiency of NeoPhectin™ in BALB/3T3 Cells

[00101] The transfection efficiency of NeoPhectin™ was evaluated using β -galactosidase reporter gene assay. After cultured in 96-well plates overnight, BALB/3T3 cells were transfected with 0.2 μ g/well of pSV- β -galactosidase vector and 0.375 to 6 μ g/well of NeoPhectin™ or Lipofectamine 2000™ in serum-free medium for 6 hours. After transfection, the liposome-DNA complex was replaced with serum-containing medium. The β -galactosidase activity was determined 24 hr after transfection and plotted against exogenous β -galactosidase standards. The results of this study (see Figure 5D) reveal that NeoPhectin™ exhibited significantly greater transfection efficiency than Lipofectamine 2000™.




Figure 5D - Transfection Efficiency of NeoPhectin™ in BALB/3T3 Cells

5. Inhibition of a Cytokine Receptor (TbRII) Expression with dsRNA Interference using NeoPhectin™ in Rat Pulmonary Microvessel Endothelial Primary Cell Culture (PLMVEC)

[00102] Rat Pulmonary Microvessel Endothelial Cells (PLMVEC) primary cell culture was used for RNAi to inhibit the production of a cytokine receptor involved in tumor formation. NeoPhectin™ was used to transfect PLMVEC cells using specific double stranded RNA (dsRNA). Cells were exposed to NeoPhectin™ and oligonucleotides at different times at 37°C in 5% CO₂. Inhibition was observed within 48 hours and inhibition increased at 72 and 96 hours (see Figure 5E)




Figure 5E - Inhibition of a Cytokine Receptor (TbRII) Expression with dsRNA Interference using NeoPhectin™ in Rat Pulmonary Microvessel Endothelial Primary Cell Culture (PLMVEC)

6. Effect of NeoPhectin™ Mediated Delivery of RNAi (200nM) Oligonucleotides in Primary Cells After 48 Hours

[00103] NeoPhectin™ was evaluated for delivery of RNAi in RLMVEC primary cells. The TbRII expression was detected using indirect immunofluorescence. Primary antibody was Rabbit anti-TbRII, and secondary antibody was Goat antiRabbit conjugated with FITC. RNAi was admixed with NeoPhectin™ and 200 nM was exposed to primary cells (see Figure 5C). The effect of NeoPhectin™ mediated delivery of the RNAi was measured by fluorescence. After 48 hours, the NeoPhectin™ treated cells exhibited markedly reduced fluorescence as compared to control cells (see Figure 5F), indicating the inhibition of the gene mediating the fluorescence within the cells. These results indicate that NeoPhectin™ can efficiently deliver RNAi to primary cells and that the RNAi can function within the cells to inhibit gene expression.




Figure 5F - Effect of NeoPhectin™ Mediated Delivery of RNAi (200nM) Oligonucleotides in Primary Cells After 48 Hours

7. NeoPhectin™ (2.5 µg/mL) Mediated Delivery of RNAi Oligonucleotides Inhibits T_{RII} Gene Expression

[00104] NeoPhectin™ was evaluated for delivery of RNAi in Primary Rat Lung Microvessel Endothelial Cells (RLMVEC), Primary Human Umbilical Vein Endothelial Cells (HUVEC), and Primary Human Pulmonary Artery Endothelial Cells (HPAEC). RNAi targeted to the T_{RII} gene was admixed with NeoPhectin™ and 2.5 µg/mL were exposed to the three cell types (see Figures 5G, 5H, and 5I). The efficiency of transfection was assessed by measuring the percent gene expression relative to control cells. The results of this experiment (see Figure 5G, 5H, and 5I) indicate that NeoPhectin™ efficiently delivered RNAi to the cells.




Figure 5G - NeoPhectin™ (2.5 µg/mL) Mediated Delivery of RNAi Oligonucleotides Inhibits T_{RII} Gene in Primary Human Umbilical Vein Endothelial Cells (HUVEC)




Figure 5H - NeoPhectin™ (2.5 µg/mL) Mediated Delivery of RNAi Oligonucleotides Inhibits T_{RII} Gene in Primary Human Pulmonary Artery Endothelial Cells (HPAEC)





Figure 5I - NeoPhectin™ (2.5 µg/mL) Mediated Delivery of RNAi Oligonucleotides Inhibits T_{RII} Gene in Primary Rat Lung Microvessel Endothelial Cells (RLMVEC)

EXAMPLE 6

[00105] This example demonstrates that the compositions of the present invention represent a novel cationic cardiolipin platform for safe and enhanced *in vitro* and *in vivo* delivery.

Introduction

Cardiolipin is a naturally occurring lipid present in heart and skeletal muscle. NeoPharm has developed new technology to synthesize cationic cardiolipin analogues (Kasireddy et al.). The phosphate groups were replaced with quaternary ammonium groups which carry positive charges. The cationic cardiolipin was further modified by introducing an oxyethylene unit to both sides of the central glycerol moiety to enhance the solubility in water and polar solvents.



Structure of cationic cardiolipin

This novel cationic cardiolipin has been used in a broad range of drug delivery systems including development of an easy-to-use formulation of liposome-entrapped c-ras antisense oligonucleotide (LErafAON-ETU) where a low toxicity and enhanced therapeutic efficacy was obtained in xenograft tumor models (Pal et al., Lei et al.). Cationic lipids are widely used as transfection reagents to deliver nucleic acid to cells. However, the usage of cationic liposome is limited due to variable transfection efficiency in cultured cells. In addition, most of the cationic lipids can not be used in gene therapy because of low transfection efficiency and/or high toxicity *in vivo*. The synthesis of cationic cardiolipin-based formulations has led to the development of novel reagents, NeoPhectin™ for *in vitro* study and NeoPhectin-AT™ for animal use. These reagents will allow users to rapidly move from cell culture to animal testing and possibly to drug development. The NeoPhectin family of products are ready-to-use formulations with small and homogenous particle size (< 200 nm).

Objectives

1. To evaluate the transfection efficiency of NeoPhectin family of products *in vivo* and *in vitro*.
2. To determine the toxicity of the NeoPhectin-AT™ in mice.
3. To determine the therapeutic efficacy of c-ras siRNA by intravenous administration using NeoPhectin-AT™ against human prostate xenograft tumor model in SCID mice.

Materials and Methods

NeoPhectin preparation - NeoPhectin™ and NeoPhectin-AT™ were prepared using thin film hydration method. Cationic cardiolipin was manufactured at NeoPharm and other lipids were purchased from Avanti Polar Lipids, Inc. The small unilamellar liposomes were obtained by sequential filter extrusion through polycarbonate membranes with 0.2 and 0.1 μm pore size. The size of the liposomes was characterized with a particle sizer (Nicomp Model 380, Santa Barbara, CA).

Cell culture - A549 (human lung cancer), PC-3 (human prostate cancer), SK-OV-3 (human ovarian cancer) and MX-1 (human breast cancer) cells were maintained in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (HI-FBS). CHO (Chinese Hamster Ovary) cells were maintained in Kaighn's modification of Ham's F12 medium (F12K) with 10% HI-FBS. BALB/3T3 (murine embryonic fibroblasts) cells were maintained in Dulbecco's Modified Eagle's Medium with 10% calf serum. HepG₂ (human hepatocellular carcinoma) cells were maintained in Eagle's Minimum Essential medium with 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids and 10% HI-FBS. All culture medium and reagents were purchased from Invitrogen (Carlsbad, CA).

In vitro transfection - One day before transfection, appropriate amount of cells (200,000 cells/well in 24-well plate for HepG₂, 10-50,000 cells/well in 96-well for other cell lines) were plated and incubated overnight in a 5% CO₂ incubator. Prior to transfection, the cells were washed to remove the serum before adding the transfection mixture.

NeoPhectin™ liposome was resuspended in OptiMEM I reduced serum medium (Invitrogen, Carlsbad, CA) in 5 mL cell culture tubes and incubated at room temperature for 5 minutes. NeoPhectin™ was added to obtain the intended PCL-2/DNA (+/-) charge ratio. The pSV- β -galactosidase (β -gal) vectors (Promega, Madison, WI) were used for the β -gal reporter gene assay in CHO, BALB/3T3 and HepG₂ cells. The gWIZ luciferase vectors (Gene Therapy System, San Diego, CA) were used for the luciferase assay in A549 and MX-1 cells. Total amount of plasmids was 0.2 μg /well in 96-well format and 1 μg /well in 24-well format. The plasmids were diluted in the same volume of OptiMEM I reduced serum medium that used to dilute NeoPhectin™. DNA solution was added drop by drop to pre-mixed NeoPhectin™ solution and incubated at room temperature for additional 30 minutes. After incubation, the DNA-NeoPhectin™ complex was added to the cells and incubated for 4-6 hr. After transfection, the DNA-NeoPhectin™ complexes were washed off and the cells were replenished with regular culture medium and incubated for up to 24 hours.

β -gal reporter gene assay was performed using β -gal Reporter Gene Assay System (Promega, Madison, WI) according to the manufacturer's protocol. The observance of the sample was read at 414 nm using a plate reader (Thermo Electronics, Franklin, VA). The amount of β -gal expression was calculated based on the exogenous β -gal standard. The expression of luciferase was measure using Luciferase Assay System (Promega, Madison, WI). The assay reagent was mixed with 20 μl cell lysate and the relative light unit (RLU) was determined by a luminometer (Thermo Electronics, Franklin, VA).

Materials and Methods (continued)

siRNA – the siRNA species that was employed in this experiment is identified in this application as Sequence No. 7:

5' -AUUCCUGCUCAAUGGAUUUdTdT-3'

3' -dTdTUAAGGACGAGUUACCUGAAA-5'

Cytotoxicity - *In vitro* studies using c-raf siRNA were conducted using NeoPhectin in A549, PC-3 and SK-OV-3 cancer cell lines. Approximately 10,000 cells/well were plated in a 96 well plate and transfected with 200nM of c-raf siRNA using 10 µg/mL of NeoPhectin™ for 6 hr. After transfection, the NeoPhectin c-raf siRNA complex was washed off and the cells were replenished with fresh medium and incubated for up to 72 hr. The cytotoxicity of c-raf siRNA was determined by sulforhodamine B assay (Monks et. al.).

In Vivo Studies - Both *in vivo* reporter gene transfection and toxicity studies were evaluated in male Balb/c mice (Charles River Laboratories, Portage, MI). Luciferase reporter gene assay was used to determine the transfection of NeoPhectin-AT™. The gWIZ luciferase vectors (50 µg/mouse) were mixed with NeoPhectin-AT™ using the same procedure as in *in vitro* study. The DNA -NeoPhectin-AT™ mixture was injected to the mice intravenously through a tail vein. A leading commercial product X was included as comparison. Lungs were removed 24 hr after injection and homogenized in Cell Culture Lysis Reagent (Promega, Madison, WI). The luciferase assay was performed as described in *in vitro* study. The protein concentration of each tissue sample was determined using RDCDC protein assay (Bio-Rad, Hercules, CA).


Toxicity - The single-dose toxicity of NeoPhectin-AT™ liposomes was evaluated by injecting mice with 100 mg/kg of NeoPhectin-AT™ liposomes through a tail vein. A leading commercial product was included for comparative analysis. The multiple-dose toxicity of NeoPhectin-AT™ was further examined by injecting mice with 50, 75 or 100 mg/kg of NeoPhectin™ liposomes via a tail vein for 3 days and the body weight and clinical signs of toxicity were monitored.

Therapeutic efficacy - Male SCID mice were transplanted with 5 x 10⁶ human prostate cancer cells (PC-3) subcutaneously. After the tumors were well established (~ 121 mm³) the mice were randomly divided into various treatment groups. These groups were treated by intravenous administration of either free siRNA or siRNA+NeoPhectin (BID) for five consecutive days. Tumor growth and body weights were measured twice a week using a caliper.

Results


LYM228272

NeoPhectin™: *In vitro* transfection



The peak activity was seen at 2:1 (+/-) charge ratio (~10 μ g/mL NeoPhectin™). Each data point was expressed as mean \pm SEM

NeoPhectin-AT™: *In vivo* transfection Following Systemic Administration



The luciferase reporter gene was transfected with product X or NeoPhectin-AT™. The lungs were removed and assayed for luciferase expression 24 hr after transfection.

Toxicity of NeoPhectin-AT™

Single-dose Toxicity (I.V. x 1)


Product	Dose (mg/kg)	Survival rate (%)
NeoPhectin-AT™	100	100
Commercial product X	100	33.3

Multiple-dose Toxicity (I.V. x 3)

Product	Cumulative Dose (mg/kg)	Survival rate (%)
NeoPhectin-AT™	150	100
	225	100
	300	66.7


Results, Continued

NeoPhectin™ mediated delivery of c-raf siRNA inhibited the cancer cell growth




c-raf siRNA (200nM) was transfected with 10 µg/mL of NeoPhectin™ for 6 hr as described in the materials and methods. The cytotoxicity was assayed 72 hr after the transfection. Each data point was expressed as mean \pm SEM.

Intravenous Administration of NeoPhectin-AT™ Based c-raf siRNA Inhibits Growth of Human Prostate Tumor in SCID Mice



Intravenous Administration of NeoPhectin-AT™ Based siRNA- Inhibits Growth of Human Prostate Tumor in SCID Mice



Conclusions

- NeoPhectin family of products were developed based on novel cationic cardiolipin, analogues of naturally occurring cardiolipin.
- NeoPhectin™, the product for *in vitro* use, transfected multiple cell lines including primary cells (for more information, see www.neophectin.com).
- NeoPhectin-AT™ has shown 5 folds higher luciferase expression in lung tissues as compared to the leading commercial product.
- NeoPhectin-AT™ has shown less toxicity as compared to a leading commercial product.
- NeoPhectin™ mediated delivery of c-raf siRNA significantly inhibited the growth of A549, PC-3 and SK-OV-3 cells.
- Intravenous administration of c-raf siRNA using NeoPhectin-AT™ indicated significant tumor growth inhibition compared to free c-raf siRNA in SCID mice xenograft model.

References

1. K. Kasireddy, et al. Cationic cardiolipin analogues for the optimal delivery of therapeutic agents. 226th ACS national meeting (2003).
2. Y. Lei, et al. Enhanced therapeutic efficacy of a novel liposome-based formulation of c-raf AON in combination with Taxol® against human ovarian tumor model in SCID mice. 95th AACR annual meeting, abstract #638 (2004).
3. A. Pal, et al. Enhanced therapeutic efficacy of liposome entrapped raf antisense oligonucleotide in combination with Taxotere® in xenograft model of human prostate cancer. 95th AACR annual meeting, abstract #637 (2004).
4. A. Monks, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766 (1991).

Abstract

Cationic lipid-based formulations have been used to deliver DNA, RNA and oligonucleotides to cells. However, the usage of cationic liposomes have been limited due to the toxicity and variable transfection efficiency. A novel cationic cardiolipin [1, 3-Bis-(1, 2-bis-tetradecyloxy-propyl-3-dimethylethoxyammonium bromide)-propane 2-ol] or PCL-2 was synthesized at NeoPharm and has been used to develop a *in vitro* (NeoPhectin™) and an *in vivo* (NeoPhectin-AT™) transfection reagents. PCL-2 is an ether analogue of cardiolipin where phosphate groups were replaced with quaternary ammonium groups resulting in positive charges. The purpose of this study was to test the applications of NeoPhectin™ *in vitro* and NeoPhectin-AT™ *in vivo*. The β -galactosidase and luciferase reporter gene assays were used to measure the *in vitro* transfection efficiencies. The *in vivo* transfection efficiency of NeoPhectin-AT™ was tested in male Balb/c mice through intravenous tail vein injection. The results showed that the transfection efficiency of NeoPhectin-AT™ was 5 folds higher than the leading commercial product as indicated by the luciferase reporter gene expression in lung tissue. In addition, NeoPhectin-AT™ was found to be less toxic than the leading commercial product. Therapeutic efficacy of c-raf siRNA using NeoPhectin-AT™ indicated a reduction in tumor size in SCID mouse model. In summary, NeoPhectin™ family of products containing cationic cardiolipin have been found to be less toxic and can be used to successfully deliver nucleic acids *in vitro* and *in vivo*.

[00106] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[00107] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[00108] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

WHAT IS CLAIMED IS:

1. A composition comprising 1,3-Bis-(1,2-bis-tetradecyloxy-propyl-3-dimethylethoxyammoniumbromide)-propane-2-ol (PCL-2) and further comprising at least one lipid selected from the group of lipids consisting of cholesterol, dioleoylphosphatidylethanolamine (DOPE), 1,2 Dioleoyl-sn-glycero-3-phosphocholine (DOPC), alpha tocopheryl acid succinate and any other phosphatidylcholine.
2. The composition of claim 1, comprising DOPC, PCL-2, and cholesterol.
3. The composition of claim 2, having a percent molar ratio of DOPC:cholesterol:PCL-2 of between about (50-65):(25-35):(5-20).
4. The composition of claim 2 or 3, further comprising D-alpha tocopheryl acid succinate
5. The composition of claim 4, wherein the D-alpha tocopheryl acid succinate is present at between about 0.1 wt % and about 1 wt %.
6. The composition of claim 1, comprising PCL-2 and cholesterol.
7. The composition of claim 6, wherein the molar ratio of PCL-2 and cholesterol is between 1:3 and 6:1.
8. The composition of claim 1, comprising PCL-2 and DOPE.
9. The composition of claim 8, wherein the molar ratio of PCL-2 and DOPE is between 1:3 and 3:1.
10. The composition of any of claims 6-9, wherein the total lipid concentration is between about 1.0 mg/mL and about 60 mg/mL.
11. The composition of any of claims 1-10, wherein the concentration of PCL-2 is about 10 mM.
12. The composition of any of claims 1-11, further comprising a sugar.

13. The composition of claim 12, wherein the sugar is sucrose.
14. The composition of claim 12 or 13, wherein the sugar is present at about 5 wt% to about 30 wt%.
15. The composition of any of claims 1-14, further comprising a carrier.
16. The composition of claim 15, wherein the carrier is a physiologically-compatible buffer.
17. The composition of any of claims 1-16, wherein a portion of the PCL-2 is present within liposomes.
18. The composition of claim 17, wherein the mean size of the liposomes is between about 50 nm and about 200 nm.
19. The composition of claim 17 or 18, wherein 99% of the liposomes have a diameter less than between about 170 nm and about 500 nm.
20. The composition of any of claims 1-19, having a pH of between about 7 and about 8.
21. The composition of any of claims 1-20, further comprising at least one active agent.
22. The composition of claim 21, wherein the active agent is a polynucleotide.
23. The composition of claim 22, wherein the polynucleotide is DNA.
24. The composition of claim 23, wherein the DNA is an oligodeoxyribonucleotide.
25. The composition of claim 24, wherein the respective charge ratio of cationic cardiolipin PCL-2:oligodeoxyribonucleotide ranges from (1.0-4.0): 1.
26. The composition of claim 24, wherein said respective total lipids to oligodeoxyribonucleotide molar amounts are (10-200):1.

27. The composition of claim 24, wherein the oligodeoxyribonucleotide contains at least one phosphothioate modification.

28. The composition of claim 24, wherein the oligodeoxyribonucleotide ranges in size from 10 to 40 nucleotides.

29. The composition of claim 28, wherein the oligodeoxyribonucleotide ranges in size from 15 to 25 nucleotides.

30. The composition according to any of claims 24-29, which comprises liposomes and wherein between 60-80% of the oligodeoxyribonucleotide is complexed with cationic lipids in the inner core of the liposomes.

31. The composition of any of claims 24-30, wherein the oligodeoxyribonucleotide has a sequence comprising 5'-GTGCTCCATTGATGC-3' (SEQ ID NO: 1).

32. The composition of claim 22, wherein the polynucleotide is RNA.

33. The composition of claim 32, wherein the RNA is RNAi.

34. The composition of any of claims 22-32, wherein the polynucleotide hybridizes to a human mRNA.

35. The composition of claim 34, wherein the polynucleotide inhibits the expression of the gene upon binding to the mRNA.

36. The composition of claim 35, wherein the mRNA is an oncogene.

37. The composition of claim 36, wherein the oncogene is selected from the group of oncogenes consisting of ras, raf cot, mos, myc.

38. The composition of claim 36 or 37, wherein the oncogene is c-raf-1.

39. A method of inhibiting the growth of neoplastic cells comprising administering the composition of any of claims 36-38 to neoplastic cells under conditions such that said polynucleotide enters said cells, whereby the polynucleotide inhibits the expression of said oncogene to which it is targeted within said neoplastic cells.

40. The method of claim 39, wherein said cells are in vitro.

41. The method of claim 39, wherein said cells are in vivo.

42. A method of treating a patient suffering from a neoplastic disease comprising administering the composition of any of claims 36-38 to said patient under conditions such that said polynucleotide enters neoplastic cells within said patient, whereby the polynucleotide inhibits the expression of said oncogene to which it is targeted within said neoplastic cells.

43. The method of claim 42, wherein said neoplastic disease comprises cancer.

44. The method of claim 42 or 43, wherein said neoplastic cells are within a tumor.

45. The method of claim 42 or 43, wherein said neoplastic cells are metastasized cells.

46. The method of any of claims 39-45, wherein the composition is administered adjunctively with a second antineoplastic agent.

47. The method of claim 46, wherein the composition is administered prior to, concurrently with, or after the second antineoplastic agent.

48. The method of claim 46 or 47, wherein the antineoplastic agent is radiation.

49. The method of claim 46 or 47, wherein the antineoplastic agent is a chemotherapeutic agent.

50. A method for validating a target gene, comprising (a) administering to a cell a composition comprising a cationic liposome and an RNAi, whereby the RNAi enters the cell inhibits the expression of a gene within the cell and (b) assaying for the inhibition of the gene.

51. The method of claim 50, wherein the composition is the composition of any of claims 1-22.

52. A fluorescent cationic cardiolipin analogue.
53. The fluorescent cationic cardiolipin analogue of claim 52, comprising a cationic cardiolipin molecule conjugated to a fluorescent/ luminescent moiety.
54. The fluorescent cationic cardiolipin analogue of claim 53, wherein the cationic cardiolipin molecule is PCL-2.
55. A luminescent cationic cardiolipin analogue.
56. The luminescent cationic cardiolipin analogue of claim 52, comprising a cationic cardiolipin molecule conjugated to a fluorescent/ luminescent moiety.
57. The luminescent cationic cardiolipin analogue of claim 53, wherein the cationic cardiolipin molecule is PCL-2.
58. A composition comprising the fluorescent/ luminescent cationic cardiolipin analogue of any of claims 52-57 and a physiologically-acceptable carrier.
59. A liposomal composition comprising the fluorescent/ luminescent cationic cardiolipin analogue of any of claims 52-57.
60. The liposomal composition of claim 58 or 59, further comprising an additional lipid.
61. The liposomal composition of any of claims 58-60, further comprising a physiologically acceptable carrier.
62. A method of tracking the migration of a lipid substance within an animal comprising (a) introducing the composition of any of claims 58-61 into an animal, (b) causing the fluorescent/ luminescent cationic cardiolipin analogue to fluoresce or luminate, and (c) observing the position of fluorescence or luminescence.
63. The method of claim 62, wherein steps (b) and (c) are repeated one or more times.
64. The use of a composition of any of claims 1-20 as a transfection agent.

65. A method of transfecting a cell with a polynucleotide, comprising exposing the cell to the composition of any of claims 22-38 under conditions sufficient for the polynucleotide present within the composition to enter the cell.

66. The method of claim 65, wherein the cell is in vitro.

67. The method of claim 60, wherein the cell is in vivo.

68. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #1

5' -UGGAAUGAGCUUACAUGACdTdT-3'
3' -dTdTACCUUACUCGAAUGUACUG-5'

69. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #2

5' -GCACGCUUAGAUUGGAACAdTdT-3'
3' -dTdTTCGUGCGAAUCUAACCUUGU-5'

70. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence#3

5' -UGCGUCGGAUGCGAGAAUCdTdT-3'
3' -dTdTACGCAGCCUACGCUCUUAG-5'

71. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #4

5' -UCCGGAUGCAGGAUGACAAdTdT-3'
3' -dTdTAGGCCUACGUCCUACUGUU-5'

72. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #5

5' -UCAACAGGAGCGCCUCUGAdTdT-3'
3' -dTdTAGUUGUCCUCGCGGAGACU-5'

73. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #6

5' -UGCUUGCACGCUGACUACAdTdT-3'
3' -dTdTACGAACGUGCGACUGAUGU-5'

74. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #7

5' -AUUCCUGCUCAAUGGAUUUdTdT-3'
3' -dTdTUAAGGACGAGUUACCUAAA-5'

75. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #8

5' -GCUGCAUCAAUGGAGCACAdTdT-3'
3' -dTdTTCGACGUAGUUACCUCGUGU-5'

76. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #9

5' -CUGCAUCAAUGGAGCACAUdTdT-3'
3' -dTdTGCAGUAGUUACCUCGUGUA-5'

77. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #10

5' -UGCAUCAAUGGAGCACAUAdTdT-3'
3' -dTdTACGUAGUUACCUCGUGUAU-5'

78. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #11

5' -GCAUCAAUGGAGCACAUACdTdT-3'
3' -dTdTTCGUAGUUACCUCGUGUAUG-5'

79. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #12

5' -GCUGCAUCA AUGGAGCACA UU-3'
3' -UUCGACGUAGUU ACCUCGUGU-5'

80. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #13

5' -CUGCAUCA AUGGAGCACA UUU-3'
3' -UUGACGUAGUU ACCUCGUGUA-5'

81. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #14

5' -UGCAUCA AUGGAGCACA UAUU-3'
3' -UUACGUAGUU ACCUCGUGUAU-5'

82. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #15

5' -GCAUCA AUGGAGCACA UACUU-3'
3' -UUCGUAGUU ACCUCGUGUAUG-5'

83. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #16

5' -GCUGCAUCAAAUGGAGCACAUAdTdT-3'
3' -dTdTTCGACGUAGUUACCUCGUGUAU-5'

84. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #17

5' -AAGCUGCAUCAAAUGGAGCACAdTdT-3'
3' -dTdTUUCGACGUAGUUACCUCGUGU-5'

85. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #18

5' -GCAUCAAAUGGAGCACAUACAGdTdT-3'
3' -dTdTTCGUAGUUACCUCGUGUAUGUC-5'

86. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #19

5' -CUGCAUCAAAUGGAGCACAUACdTdT-3'
3' -dTdTGACGUAGUUACCUCGUGUAUG-5'

87. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #20

5' -AAGCUGCAUCAAAUGGAGCACAUACdTdT-3'
3' -dTdTUUCGACGUAGUUACCUCGUGUAUG-5'

88. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #21

5' -GCUGCAUCAAAUGGAGCACAUACAGdTdT-3'
3' -dTdTTCGACGUAGUUACCUCGUGUAUGUC-5'

89. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #22

5' -GCAUCAAAUGGAGCACAUACAGGGAdTdT-3'
3' -dTdTTCGUAGUUACCUCGUGUAUGUCCCU-5'

90. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #23

5' -UUAAGCUGCAUCAAAUGGAGCACAUdTdT-3'
3' -dTdTAAUUCGACGUAGUUACCUCGUGUA-5'

91. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #24

5' -GCUGCAUCAAAUGGAGCACAUUU-3'
3' -UUCGACGUAGUUACCUCGUGUAU-5'

92. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #25

5' -AAGCUGCAUCAAAUGGAGCACAUU-3'
3' -UUUUCGACGUAGUUACCUCGUGU-5'

93. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #26

5' -GCAUCAAAUGGAGCACAUACAGUU-3'
3' -UUCGUAGUUACCUCGUGUAUGUC-5'

94. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #27

5' -CUGCAUCAAAUGGAGCACAUACUU-3'
3' -UUGACGUAGUUACCUCGUGUAUG-5'

95. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #28

5' -AAGCUGCAUCAAAUGGAGCACAUACUU-3'
3' -UUUUCGACGUAGUUACCUCGUGUAUG-5'

96. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #29

5' -GCUGCAUCAAAUGGAGCACAUACAGUU-3'
3' -UUCGACGUAGUUACCUCGUGUAUGUC-5'

97. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #30

5' -GCAUCAAAUGGAGCACAUACAGGGAUU-3'
3' -UUCGUAGUUACCUCGUGUAUGUCCCU-5'

98. The composition of claim 33, wherein the RNAi comprises the following sequence:

Sequence #31

5' -UUAAGCUGCAUCAAAUGGAGCACAUUU-3'
3' -UUAUUCGACGUAGUUACCUCGUGUA-5'

99. The composition of any of claims 1-98, comprising a plurality of active agents.

100. The composition of claim 99, wherein at least two active agents comprise nucleic acids.

101. The composition of claim 100, wherein at least one of said nucleic acids is an siRNA species.

102. The composition of claim 100, wherein at least one of said nucleic acids is an oligonucleotide.

103. The composition of any of claims 100-102, wherein a first and a second nucleic acids target separate genetic sequences.

104. The composition of claim 103, wherein the separate genetic sequences are found in separate genes.

105. The composition of claim 103, wherein the separate genetic sequences are found in the same gene.

ABSTRACT

The invention provides a composition, suitable for use as a transfection agent, comprising a cationic cardiolipin analogue and, desirably, another lipid species. The composition of the present invention can facilitate transfection of a wide variety of polynucleotide species (e.g., oligodeoxyribonucleotides, plasmids, RNAi species, etc.). Moreover, the transfection agent of the present invention is effective in promoting transfection of primary cell cultures as well as transformed cells. Also, the inventive transfection agent is suitable for use both *in vitro* and *in vivo*. The inventive composition has additional uses as well, such as delivery of a variety of active agents, dermatological and cosmetic uses, and uses in agriculture.

A preferred cationic cardiolipin is 1,3-Bis-(1,2-bis-tetradecyloxy-propyl-3-dimethylethoxyammoniumbromide)-propane-2-ol (PCL-2). The composition further preferably comprises a lipid selected from the group of lipids consisting of cholesterol, dioleoylphosphatidylethanolamine (DOPE), 1,2 Dioleoyl-sn-glycero-3-phosphocholine (DOPC), alpha tocopheryl acid succinate and phosphatidylcholine. The composition can include an active agent, such as a polynucleotide. The present invention also involves pharmaceutical formulations of c-raf Antisense Oligonucleotide (c-rafAON) and methods for making stable lamellar complexes of an antineoplastic agent to minimize rapid hydrolysis of raf-AON in plasma, reduce *in vivo* clearance, improve cell transfection and increase therapeutic efficacy of c-rafAON.


The invention further provides a method of introducing an active agent into a cell by contacting the cell with the inventive composition. The invention further provides a method of inhibiting the growth of neoplastic cells and a method of treating a patient suffering from a neoplastic disease by employing the inventive composition, wherein an active agent is an antineoplastic agent. The invention further provides a method for validating a genetic target, comprising (a) administering to a cell a composition comprising a cationic liposome and an RNAi, whereby the RNAi enters the cell inhibits the expression of a gene within the cell and (b) assaying for the inhibition of the gene.

The method also provides a fluorescent/ luminescent cationic cardiolipin analogue and compositions including such analogues. Using a cationic cardiolipin analogue, the invention provides a method of tracking the migration of a lipid substance within an animal.


LErafAON-ETU Manufacturing Process

The manufacturing process for LErafAON –ETU is shown in the flow chart (Figure 1). This process involves dissolving : i) the lipid excipients, namely, DOPC, cholesterol, (*R*)-PCL2 and D-Alpha tocopheryl acid succinate in dehydrated ethanol and ii) the active ingredient , rafAON, and sucrose in sterile water for injection. Ethanolic lipid solution is added to aqueous active solution to form liposomes. Following QS to batch weight, liposomes are extruded to meet size specifications and ethanol is removed by rotary evaporation. After adjusting the batch weight to pre-solvent removal weight, the product is filtered through 0.22 μ sterilizing filter and filled in sterile vials, stoppered and sealed.

Figure1. Manufacturing Process Flow-chart for LErafAON-ETU Formulation




Therapeutic Efficacy of DDAB-Liposome or Cationic Cardioliipin Liposome-Based Antisense Oligonucleotide (AON) in combination with Taxotere® against Human Prostate (PC-3) Tumor Growth in SCID Mice*



Treatment
DDAB Liposome or Cationic Cardioliipin Liposome-Based AON Formulations (25 mg/kg, BID X 5)
Taxotere®: Day 2, (10 mg/kg), Day 5, (5 mg/kg)

*Obtained from Harlan Sprague Dawley, Indianapolis, IN

Effect of DDAB-Liposome or Cationic Cardioliipin Liposome- Based Antisense Oligonucleotide (AON) in Combination with Taxotere® Against Human Prostate (PC-3) Tumor in SCID Mice



Treatment

DDAB or Cationic Cardioliipin Liposome-based AON (12.5 mg/kg, BID x 5)
Taxotere® Day 2 (10 mg/kg), Day 5 (5 mg/kg)

Figure 4B

Toxicity of DDAB*-Liposome or Cationic Cardiolipin Liposome-Based Antisense Oligonucleotide (AON) in Mice^T

Test Article**	Dose (mg/kg/day)***	Number of Mice	%Survival Male	%Survival Female
DDAB Liposome- Based AON	35	10	0	60
Cationic Cardiolipin Liposome-Based AON	35	10	90****	100

*Dimethyldioctadecyl ammonium bromide

**Control- 100% Survival

***17.5 mg/kg, BID X 5

****Animal died due to technical error

^T Obtained from Charles River, Wilmington, MA

Figure 4C

Application Data Sheet

Inventor Information

Inventor One Given Name:: Moghis U.
Family Name:: AHMAD
Mailing Address Line One:: 3050 North Forest Hills Ct.
City:: Wadsworth
State or Province:: Illinois
Postal or Zip Code:: 60083
Country:: US
Citizenship Country:: US

Inventor Two Given Name:: Saifuddin
Family Name:: SHEIKH
Mailing Address Line One:: 1059 South West Avenue
City:: Waukegan
State or Province:: Illinois
Postal or Zip Code:: 60085
Country:: US
Citizenship Country:: US

Inventor Three Given Name:: Shoukath M.
Family Name:: ALI
Mailing Address Line One:: 39120 North Ogden Lane
City:: Beach Park
State or Province:: Illinois
Postal or Zip Code:: 60083
Country:: US
Citizenship Country:: India

Inventor Four Given Name:: Pèi-Yu
Family Name:: CHIEN
Mailing Address Line One:: 760 Pleasant Avenue
City:: Highland Park
State or Province:: Illinois
Postal or Zip Code:: 60035
Country:: US
Citizenship Country:: US

Inventor Five Given Name:: Haris
Family Name:: JAMIL
Mailing Address Line One:: 1216 Trinity Place
City:: Libertyville
State or Province:: Illinois
Postal or Zip Code:: 60048
Country:: US
Citizenship Country:: US

Inventor Six Given Name:: Jia-Ai
Family Name:: ZHANG
Mailing Address Line One:: 1251 Maidstone
City:: Vernon Hills
State or Province:: Illinois
Postal or Zip Code:: 60061
Country:: US
Citizenship Country:: US

Inventor Seven Given Name:: Sydney
Family Name:: UGWU
Mailing Address Line One:: 4005 Stoney Island
City:: Gurnee
State or Province:: Illinois
Postal or Zip Code:: 60031
Country:: US
Citizenship Country:: Nigeria

Inventor Eight Given Name:: Zhi-Yi
Family Name:: ZHANG
Mailing Address Line One:: 7986 Dada Avenue
City:: Gurnee
State or Province:: Illinois
Postal or Zip Code:: 60031
Country:: US
Citizenship Country:: People's Republic of China

Inventor Nine Given Name:: Jinkang
Family Name:: WANG
Mailing Address Line One:: 39 Inverness Drive
City:: San Francisco
State or Province:: California
Postal or Zip Code:: 94132
Country:: US
Citizenship Country:: US

Inventor Ten Given Name:: Shastri
Family Name:: BHAMIDIPATI
Mailing Address Line One:: 2380 Chambound Drive
City:: Buffalo Grove
State or Province:: Illinois
Postal or Zip Code:: 60089
Country:: US
Citizenship Country:: US

Inventor Eleven Given Name:: Zafeer
Family Name:: AHMAD
Mailing Address Line One:: 2933 North Augusta Drive
City:: Wadsworth
State or Province:: Illinois
Postal or Zip Code:: 60083
Country:: US
Citizenship Country:: US

Inventor Twelve Given Name:: Imran
Family Name:: AHMAD
Mailing Address Line One:: 4731 West Pebble Beach Drive
City:: Wadsworth
State or Province:: Illinois
Postal or Zip Code:: 60083
Country:: US
Citizenship Country:: US

Correspondence Information

Customer Number:: 000023460
Phone:: (312) 616-5600
Fax:: (312) 616-5700
Electronic Mail:: mail@leydig.com

Application Information

Title Line One:: LIPID COMPOSITIONS AND USE THEREOF
Total Drawing Sheets:: 4
Formal Drawings:: Yes
Docket Number:: 228272
Application Type:: Provisional
Subject Matter:: Utility
Secrecy Order in Parent Appl.?:: No

Representative Information

Representative Customer Number :: 23460

Assignee Information

Name of First Assignee: NeoPharm, Inc.
Address Line One:: 150 Field Drive
City:: Lake Forest
State or Province:: Illinois
Postal or Zip Code:: 60045
Country:: US

From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

HEFNER, M. Daniel
LEYDIG, VOIT & MAYER, LTD.
180 North Stetson Avenue
Two Prudential Plaza
Suite 4900
Chicago, Illinois 60601-6780
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 10 March 2005 (10.03.2005)	
Applicant's or agent's file reference 232362	IMPORTANT NOTIFICATION
International application No. PCT/US05/000418	International filing date (day/month/year) 07 January 2005 (07.01.2005)
International publication date (day/month/year)	Priority date (day/month/year) 07 January 2004 (07.01.2004)
Applicant NEOPHARM, INC. et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable)* The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable)* An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
07 January 2004 (07.01.2004)	60/535,042	US	18 February 2005 (18.02.2005)
27 March 2004 (27.03.2004)	60/556,843	US	18 February 2005 (18.02.2005)
29 March 2004 (29.03.2004)	60/557,232	US	21 February 2005 (21.02.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Fahy Laurence

Facsimile No. +41 22 740 14 35

Facsimile No. +41 22 338 71 30
Telephone No. +41 22 338 9617

From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

HEFNER, M. Daniel
LEYDIG, VOIT & MAYER, LTD.
180 North Stetson Avenue
Two Prudential Plaza
Suite 4900
Chicago, Illinois 60601-6780
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 28 February 2005 (28.02.2005)	
Applicant's or agent's file reference 232362	IMPORTANT NOTIFICATION
International application No. PCT/US05/000418	International filing date (day/month/year) 07 January 2005 (07.01.2005)
International publication date (day/month/year)	Priority date (day/month/year) 07 January 2004 (07.01.2004)
Applicant NEOPHARM, INC. et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable)* The letters "NR" appearing in the right-hand column denote a **priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau** under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, **the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.**
- (If applicable)* An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a **priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b)** (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
07 January 2004 (07.01.2004)	60/535,042	US	18 February 2005 (18.02.2005)
27 March 2004 (27.03.2004)	60/556,843	US	18 February 2005 (18.02.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Safi Horiya

Facsimile No. +41 22 740 14 35

Facsimile No. +41 22 338 71 30
Telephone No. +41 22 338 8137